• By Michael Borella

    This Internet has gone through many revolutions, technical and otherwise.  Each time it has emerged stronger and more robust than before.  One can trace the origins of the Internet to the connection of four computers in 1969.  The advent of email a few years later, the standardization of TCP/IP as its communication protocol in the mid-1980s, commercial dialup service providers not long after that, the popularization of the World Wide Web in 1993, and the immediately-following rise of ecommerce gave us the main aspects of what we currently think of as the Internet.  Inexpensive broadband, the search engine, online gaming, social media, widespread mobile access, and videoconferencing bring us to today.

    The next Internet revolution is being driven by generative AI, and it is happening right now.  While we cannot say what is going to be in place on the other side of this inflection point, we do know that our online experience will be different in a few years.

    Consider just the web.  It relies on an economic model that has been largely static for over two decades.  But generative AI is already beginning to disrupt this model.  Today, publishers and search engines have a mostly symbiotic relationship.[1]  They need each other.  But what happens when AI is used to subsume publisher content?

    Publishers (including small and independent publishers, blogs, businesses, and so on) seek to be highly ranked in search engines, especially for search terms that are relevant to their content.  For example, an independent newsletter that reviews cars (as just one example) would want to appear as high as possible (preferably in the top ten) search results for queries involving the word "car", "automobile", "motor", and so on.  This will drive traffic to the publisher's newsletter, allowing the publisher to sell ads and/or subscriptions.  With the resulting revenue, the publisher can grow its newsletter by hiring more writers and editors, who in turn produce more content.  This content, if of sufficient quality, makes it more likely that the publisher will be highly ranked in search results — a virtuous cycle.

    Search engines (or more correctly, search engine providers) crawl the web and use sophisticated algorithms to rank publishers in terms of their sites' relevance to search terms.  A successful search engine may receive billions of search requests per day from users who want to be referred to relevant publishers.  Each page of search results may be an ordering of links to publishers and perhaps a short description or summary of the content that can be found by following each link.  Search engines make money by displaying advertisements as sponsored links.  They also allow publishers to bid on search terms in a form of auction.  The publisher who bids the highest for a given search term often ends up at the top of the search result as a sponsored link, assuming that their content is indeed relevant to the search term.

    While this symbiosis has not yet been broken, it is getting wobbly.  It is no coincidence that the largest investors in generative AI are the companies that own and operate the largest search engines.  OpenAI, which is nearly half-owned by Microsoft, has admitted to training its GPT series of models on content that it absorbed from publishers on the Internet, often without their permission.  Some would contend that the models that underlie the popular ChatGPT generative AI tool have been trained on the Internet as a whole.[2]  Indeed, The New York Times and other publishers have sued OpenAI and Microsoft for allegedly violating their copyrights and (at least in the case of the Times) allegedly producing near-verbatim copies therefore in response to large language model (LLM) prompts.[3]

    Search engine results recently changed from being a series of links to publisher sites (with ad-sponsored results on top and clearly flagged) to leading with a generated AI overview as the leading result.  This overview seeks to answer the searcher's question or address their need without requiring them to click on links and visit publisher web sites.  So far, AI overview sections have also been displaying what the underlying AI model infers to be the most relevant publisher links and/or those used a source material for the overview.

    In isolation, AI-generated search results are neither here nor there.  Users might appreciate having them summarize publisher content to provide results in a more convenient and readily-consumable form.  Of course, the generation and providing of these results is still clearly experimental and subject to the same incorrectness, hallucinations, and bias that plague LLMs.  But users may further appreciate not having to navigate to certain publisher sites that display annoying ads or are sophisticated clickbait.

    At this point it seems safe to assume that the quality of these AI summaries will continue to improve.  If so, at what point does this impact the publishers?  The news industry — one of the biggest and most important publishing sectors — has lost one-third of its newspapers and two-thirds of its news journalists in the last two decades, mostly in the area of local news.[4]  AI is likely to accelerate this decline, with search engines absorbing user traffic rather than directing it to publisher sites.  As a result, publishers are likely to have less ad revenue and fewer subscriptions, putting their businesses at risk.

    Given that a sea change toward AI-generated search results is playing out in real time, it is difficult to predict what the economic model the web will be based on five years from now.  However, we can game out a few possible scenarios.

    • Search engines use AI to subsume the publishing industry.  Publishers go out of business en masse, leaving only the LLMs that generate news-like search results.  Many view this possible future as dystopian and potentially dangerous for society without the fourth estate, as there would be fewer incentives to subsidize investigative journalism that seeks to root out corporate and governmental corruption.  In a world without news organizations, it would be extraordinarily difficult to determine "the truth" as we would rely mostly on second and third hand accounts and other forms of hearsay.  Ironically, this would also reduce the utility of search engines, likely resulting in a revenue drop for those companies as well.

    • In a slightly less dystopian future, publishing does not die but instead gets sorted into two camps.  The first are traditional publishers with large audiences, like the Times, who survive due to their name recognition and quality journalism.  The second consists of small independent publishers with niche audiences that survive on subscriptions.  Both have the ability to be a source of real-time "hot" news that is too fresh for the AI models to ingest.  They also can serve as destinations for users (e.g., the users check their apps or bookmarked links frequently), allowing the publishers to flourish even without referrals from search engines.  This has been referred to as the "barbell" strategy, where the sweet spots for publishers are at either end of the spectrum in terms of size (the very large media companies or the very small independents) with very little in between.

    • Another dark scenario is that the search engines buy up most or all major publishers, reorienting the publishing business from serving the public directly toward generating training data for AI models.  While the incentives here are complex, it is likely that the search engine companies would have at least some control over reporting.  This could lead to less reporting on any negative externalities associated with these companies or — even worse — different "facts" being used to train different search engines.  If this notion seems far-fetched, keep in mind that the Washington Post is owned by Amazon founder Jeff Bezos[5] and that Meta was considering the purchase of Simon & Schuster to train its models.[6]

    • A more likely path forward is that the search engine providers (and AI companies in general) sign licensing deals with major publishers in order to access and use their content.  This is already happening, as the Financial Times, News Corp., Axel Springer, Le Monde, Prisa Media, and The Associated Press have all agreed to license their content to OpenAI.

    • Another possibility is that search engine providers are legally prohibited from unauthorized ingestion of publisher content without permission, which makes the licensing discussed above even more appealing.  This might be a consequence of a victory for the Times in its dispute with OpenAI.

    Right now, it is too early to tell which of these scenarios may play out, or if a different one arises.  If anything, we can be certain that the business model of the Internet will be different in five years or less.  Search engines will return AI-generated answers with less emphasis of links to source material, publishers will need to engage more directly with their audience and supply a continuous stream of high-quality content, and search-engine optimization may become obsolete.

    Like all disruptions, AI search comes with opportunities as well. As the technological and legal landscape evolves we should not be surprised if new models of publishing emerge, adapted to this evolution.

    [1] This is an admittedly a simple overview of the relationship.  There is quite a bit more nuance, but this level of detail is sufficient for the discussion that follows.

    [2] https://futurism.com/the-byte/ai-training-data-shortage.

    [3] https://www.patentdocs.org/2024/02/the-new-york-times-case-against-openai-is-different-heres-why.html.

    [4] https://localnewsinitiative.northwestern.edu/posts/2024/05/08/ai-local-news-report/index.html.

    [5] https://www.theguardian.com/media/2023/jan/29/tech-moguls-media-jeff-bezos-washington-post.

    [6] https://www.theguardian.com/books/2024/apr/09/meta-discussed-buying-publisher-simon-schuster-to-train-ai.

  • By Michael Borella and Joshua Rich

    GPT-4oIt seems like every week brings a new dispute over artificial intelligence (AI), mostly focused around new features and uses of generative AI.  Last week was no exception, with OpenAI unveiling human-like voices soon being available in its GPT-4o multimodal language model.  In what would turn out to be one of the biggest tech executive self-owns this side of Elon Musk, OpenAI CEO Sam Altman tweeted (Xed?) the single word "her" on the same day that the new feature was announced.

    Almost immediately, the public put together the dots.  One of the GPT-4o voices, named Sky, was eerily similar to that of actress Scarlett Johansson, and Johansson had supplied the voice for an AI voice assistant in the 2013 Spike Jonze movie, Her.[1]  Johansson released a statement stating that Altman had been in contact with Johansson for months, seeking to use her voice in what would become GPT-4o.  Johansson had repeatedly refused.

    OpenAI responded to the controversy by "pausing" the use of Sky with its new model, then later stating that they used a voice actor to develop Sky and did not intentionally mimic Johansson's voice.[2]

    If she were to take OpenAI to court, Johansson would have a good case.  Despite copyright law not providing protection for one's voice, the common law may (at least in California).  There is clear precedent arising out of similar attempts to mimic a celebrity's voice when the celebrity chose not to participate.

    In 1985, the Ford Motor Company created an ad campaign for one of its cars.  Ford asked singer Bette Midler to sing one of her own songs in the commercials, but Midler's agent categorically refused on her behalf.[3]  Undeterred, Ford hired one of Midler's former backup singers to record Midler's song, Do You Want to Dance, for the commercial.  The backup singer was asked to sound as much as possible like Midler.  When the commercials aired, many people felt the voice in the commercial sounded exactly like Midler's; some believed that it was Midler singing.

    Midler filed suit claiming violation of the California common law right of publicity.  The District Court granted summary judgment to Ford, finding no legal principle protecting imitation of a famous voice, as opposed to using the famous person's own voice (which could amount to copyright infringement) or physical image (which was protected by both statute and common law in California).

    But Midler won a reversal on appeal to the 9th Circuit, the panel holding that "California will recognize an injury from an appropriation of the attributes of one's identity."[4]  The panel wrote:

    A voice is as distinctive and personal as a face.  The human voice is one of the most palpable ways identity is manifested.  We are all aware that a friend is at once known by a few words on the phone . . . .  A fortiori, these observations hold true of singing, especially singing by a singer of renown.  The singer manifests herself in the song.  To impersonate her voice is to pirate her identity.

    We need not and do not go so far as to hold that every imitation of a voice to advertise merchandise is actionable.  We hold only that when a distinctive voice of a professional singer is widely known and is deliberately imitated in order to sell a product, the sellers have appropriated what is not theirs and have committed a tort in California.[5]

    If the Midler case establishes that it would be illegal to deliberately imitate the distinctive voice of a professional singer who is widely known, a question remained as to who would be considered "widely known."  A few years later, some limits were added to that inquiry.

    Singer Tom Waits emerged from folk music in the 1970s with a signature gravelly voice and songs about the darker sides of society.  Though an inductee into the Rock and Roll Hall of Fame, Waits is nowhere near as famous as Midler, and has what could be described as "cult" following despite his songs being widely licensed.[6]

    Frito-Lay created a radio commercial for a new variation of its Doritos chips.  It asked Waits to provide his voice to the commercial, but he refused.[7]  So Frito-Lay hired a Waits imitator to provide the soundtrack for the commercial.

    Waits sued and was awarded $2.6 million at trial.  On appeal, the 9th Circuit affirmed the decision, stating that the trial court properly instructed the jury that a widely known voice "is known to a large number of people throughout a large geographic area."[8]

    Notably, Midler and Waits could not have prevailed on grounds of copyright infringement.  Ford had obtained a copyright license from the writers of Midler's song, and Waits did not own the copyright to his.  But their claims on grounds of right to publicity might not be available to any professional singer, only to those with distinctive and widely known voices.

    Although Johansson is a singer,[9] her speaking voice is at issue in her dispute with OpenAI.  Nonetheless, the Midler and Waits cases provide a persuasive foundation for concluding that OpenAI violated her publicity rights.  Like in those cases, she was asked for permission to use her voice, refused, and the other party hired someone with a remarkably similar voice.  Further, Johansson's voice is distinctive and widely known from her three decades as an actress.  And perhaps most importantly, her voice had been "Her"[10] voice — the paradigm of an AI voice.  Thus, OpenAI would have enjoyed the commercial benefit of Johansson's implicit endorsement of its technology even though it had failed to obtain her approval.

    As artists and creatives wrestle with how to deal with generative AI models being trained on their works and potentially spitting out substantially similar versions thereof, the Midler and Waits line of cases provides yet another arrow in the legal quiver to protect their life's work.  The difference is that an AI model could be trained to replicate a famous person's voice rather than a sound-alike human being found.[11]  Nonetheless, it remains unclear what level of celebrity is required to trigger a claim.  Less well known or regional singers or voice actors may not qualify, for example.

    Also, right to publicity laws overlap to some extent with emerging anti-deepfake legislation.  The latter may be more readily available to less famous individuals — for example, the proposed "No Fakes Act of 2023" provides a cause of action and remedies for a deepfake victim so long as they are "a human being, living or dead."[12]

    Thus, before long, you may not need to be an Avenger to take on Sam Altman.

    [1] Ironically, Her was dystopian and did not have a happy ending; it is not a good comparison for a company trying to sell the benefits of AI to the world.

    [2] A comparison of the two voices can be found here.  Sky does sound robotic, but the resemblance is clear.

    [3] According to the court records, "[t[he conversation went as follows:  'Hello, I am Craig Hazen from Young and Rubicam.  I am calling you to find out if Bette Midler would be interested in doing . . . ?' [Midler’s agent]:  'Is it a commercial?'  'Yes.'  'We are not interested.'"

    [4] Midler v. Ford Motor Co., 849 F.2d 460 (9th Cir. 1988).

    [5] Id., 849 F.2d at 463.

    [6] Ironically, Waits had an on-and-off romantic relationship with Midler.

    [7] Waits was very outspokenly against using his voice or music in commercials.

    [8] Waits v. Frito-Lay, Inc., 978 F.2d 1093, 1102 (9th Cir. 1992).

    [9] More irony:  Johansson is a fan of Waits and has covered his songs.

    [10] In the movie, the name behind the voice was Samantha.

    [11] There was just such a dispute one week earlier, when Drake used an AI replica of the voice of the deceased (or allegedly so) rapper Tupac Shakur, as well as an AI replica of the voice of the living rapper Snoop Dogg, in his diss track "Taylor Made Freestyle."  The Shakur estate threatened to sue Drake and he took the track down from social media immediately.

    [12] Tennessee has enacted the Ensuring Likeness, Voice, and Image Security (ELVIS) Act to protect the voices of singers and other musicians, both living and dead.

  • By Kevin E. Noonan –

    Judge Newman_1Suspended Federal Circuit Judge Pauline Newman's lawsuit (see "Judge Newman and the On-Going Attempts to Remove Her from the Federal Circuit") against Chief Judge Kimberly Moore, and Circuit Judges Sharon Prost and Richard Taranto (in their roles as members of the Special Committee of the Judicial Council of the Federal Circuit responsible for the Order suspending Judge Newman) soon may be reaching an important milestone:  the District Court overseeing Judge Newman's complaint will rule on Defendant Committee's motion to dismiss the remaining Counts (see "Judge Newman's Suit Continues"), now that the Committee recently filed its Reply brief to Judge Newman's opposition to its motion.

    Federal Circuit SealThe Committee begins its argument regarding Judge Newman's constitutional challenge in Counts VII and IX by asserting that orders issued under the statute are per se reasonable and do not implicate the Fourth Amendment:  "The statutory scheme ensures that orders issued in the ordinary course of investigations will be reasonable, the touchstone of the Fourth Amendment inquiry" they contend.  Further, the Reply asserts the standard that the statute must be unconstitutional in all its applications for Judge Newman to prevail, which suggests that the Committee's position is that the statute cannot be applied in a particular instance that contravenes a judge's Fourth Amendment rights, and because there are "multiple applications of 28 U.S.C. § 353(c)'s investigation provision that are undisputedly constitutional" Judge Newman's facial challenge cannot prevail.  Statutory support for the Committee's position includes that "the special committee is authorized to 'conduct an investigation as extensive as it considers necessary'" 28 U.S.C. § 353(c) which is not limited to the issues presented by Judge Newman relating to "medical examinations and private medical records," and that the "no set of circumstances" test for unconstitutionality in United States v. Salerno, 481 U.S. 739, 745 (1987), is controlling and supported by City of Los Angeles v. Patel, 576 U.S. 409 (2015), and Wash. State Grange v. Wash. State Republican Party, 552 U.S. 442, 449 (2008).  Another statutory basis on which the Committee relies is that "in the absence of § 353's authority" the Committee "cannot even exist."  The Committee's argument implies that Judge Newman had the burden to show that any action by the Committee would be unconstitutional ("certainly all coercive investigative steps"), thus apparently interpreting both the statute to authorize and the process to require investigative steps to be coercive.  Under this interpretation, the Committee argues that the statute expressly provides its authority to take such steps, even to the extent they would otherwise violate a judge's Fourth Amendment rights.

    The Committee rests its defense to Judge Newman's assertions of unconstitutionality on whether its actions are "reasonable," which it argues "depends on the context within which a search takes place," citing New Jersey v. T.L.O., 469 U.S. 325, 337 (1985), and cites authority "outside the 'crime control' context" in support (Indianapolis v. Edmond, 531 U.S. 32, 44 (2000)); see, e.g., National Treasury Employees Union v. Von Raab, 489 U.S. 656, 679 (1989)) (each of which involve employees).  This involves a "balancing test" between "the nature and quality of the intrusion on the individual's Fourth Amendment interests against the importance of the governmental interests alleged to justify the intrusion," the Committee argues, citing O'Connor v. Ortega, 480 U.S. 709, 719–20 (1987) (plurality op.) (quoting United States v. Place, 462 U.S. 696, 703 (1983)), spurred by the existence of governmental "special needs" wherein requiring the government to obtain a warrant would be "impracticable."  Regarding this requirement, the Committee argues that "finding a warrant requirement impracticable in a particular context is a possible result—not a necessary precondition—of an assertion of special needs."

    The Reply also asserts that Judge Newman was entitled to "precompliance review" of the order, stating that "[a] judge subject to a special committee's investigative order under § 353(c) thus has ample 'opportunity to obtain precompliance review' of that order by challenging it before the neutral decisionmaker[s]' of the judicial council prior to the imposition of any penalty for noncompliance" under Patel.  (While perhaps true, these assertions seem to ignore the imposition of the consequence of non-compliance — suspension — because Judge Newman exercised her right not to merely comply and does not address Judge Newman's assertions that the Special Committee of the Federal Circuit Judicial Council was not a "neutral decisionmaker" but instead "investigator, judge, and jury—and even, if necessary, witnesses.")

    The Reply also asserts that Judge Newman could have "availed herself of the opportunity for Judicial Conference review by the judges drawn from across the country" under 28 U.S.C. § 331; id. § 357(a) (permitting a "judge aggrieved by an action of the judicial council under section 354" to petition the Judicial Conference); Rule 21(b)(1) (permitting a subject judge to petition the Judicial Conference's Committee on Judicial Conduct and Disability to review judicial council actions such as censures or suspensions); see Memorandum of Decision at 40, In re: Complaint of Judicial Misconduct, C.C.D. 17-01 (Comm. on Jud. Conduct & Disability Aug. 14, 2017)" (but note a seeming contradiction in the Committee's position discussed below).  This factual disagreement is important because its existence is one of the bases for the Committee's argument that there is no Fourth Amendment violation by the Committee's actions ("These opportunities for precompliance review of a special committee's § 353(c)'s orders by neutral adjudicators render the statute consistent with the Fourth Amendment's requirements especially for § 353(c) orders that (as was true of the orders Plaintiff focuses on) are issued with individualized suspicion that the subject of the search had triggered the governmental need at issue.")  That factual disagreement encompasses Judge Newman's contentions that:

    Chief Judge Moore "unilaterally" removed Judge Newman from the bench, the suspension being "extended by an unprecedented, unrecorded and unpublished vote of the Defendant Judicial Council" in a meeting that was "neither noticed nor memorialized."  Only after this suspension, the brief asserts, did the Chief Judge "instigate[]" an investigation over alleged physical infirmities (a heart attack and a fainting episode) that "Defendants themselves now acknowledge were false."  [See "Judge Newman's Suit Continues".]

    by asserting that "no § 353(c) investigation can even begin absent a finding of "probable cause" that the subject judge suffered from a disability within the meaning of the Act" and "[t]he individualized suspicion accompanying the types of investigative orders under § 353(c) that Plaintiff challenges strongly reinforces the reasonableness of searches conducted per such orders."

    The Reply justifies the Committee's actions here based on the:

    "significance of the core interest Defendants advanced:  ensuring that judges entrusted with the power to render decisions profoundly affecting the public in both immediate and lasting ways—e.g., issuing bail decisions, depriving individuals of liberty or property, making factual findings subject only to deferential review—do not suffer from disabilities that render them "unable to discharge all the duties of office" (or that they have not "engaged in conduct prejudicial to the effective and expeditious administration of the business of the courts").  28 U.S.C. § 351(a)"

    (generalizing the issue to all judges rather than specifically to Judge Newman, i.e., in how these principles impact and were applied to the Judge in this instance).

    The Reply also seems to assert that there is "[an]other side of the ledger" between the distinctions Judge Newman raised between an Article III judge and a government employee ("as an Article III judge she is a 'constitutional officer of this Republic, and not merely a federal employee' who 'does not have a supervisor and does not need to meet any performance metrics to keep her job'") insofar as that status imposes a quid pro quo that a judges privacy interests are "qualified by the acceptance of a life-tenured judicial position" wherein their "lives and careers are routinely scrutinized during the confirmation process, and the same goes for their financial arrangements throughout their judicial tenure" and "investigations into misconduct or potential disability are fully authorized by the Act, and thus an established component of life tenure on the federal bench."  In this regard, the Committee casts the dispute as one in which while Judge Newman's privacy interests must be given "weight," "they do not categorically trump the legitimate and significant objectives advanced by the statute, as they would have to do for Plaintiff to prevail in her facial challenge."  In this regard, the Reply also notes that the provisions of § 353(c) are not "confined to investigations of Article III judges; it applies equally to magistrate judges and bankruptcy judges who do not enjoy life tenure or the constitutional status on which Plaintiff rests her argument."  And the Reply turns Judge Newman's argument on its head, wherein the special role of the judiciary "underscores the importance of having investigatory means like those in the Act—which were deliberately designed to respect the special independence of the Judicial Branch—to uncover and address disability or misconduct among Article III judges" because of "the absence of the usual mechanisms for terminating an employee who cannot fulfill their duties."

    The Reply attempts to rebut Judge Newman's argument that she was entitled "to resort to outside judicial officers to conduct even basic investigatory steps" by the need for expediency under the circumstances of purported judicial disability.  However, this argument also seems to implicate the issue of compliance and Judge Newman's ability for challenging such "basic investigatory steps" that the Reply earlier asserted the Act provided.  While it may be the case that "[r]equiring resort to judicial officers outside the congressionally defined judicial conduct and disability mechanism would functionally constitute the type of outside as-applied challenge that Congress has plainly and constitutionally deemed inconsistent with the Act's streamlined judicial "housekeeping" mechanisms," how else would Judge Newman have been about take advantage of the means provided for the Act (according to the Reply) to challenge the committee's requirements?

    Turning to Judge Newman's Count V challenge of the disability provisions of the statute for vagueness, the Reply renews its argument that Judge Newman fails the requirement of a facial challenge to show that "the law in question is impermissibly vague in all of its applications," citing Crooks v. Mabus, 845 F.3d 412, 417 (D.C. Cir. 2017).  On the merits, the Reply argues that the Act is not constitutionally vague because the Act permits a judicial council to "take action where a 'judge is unable to discharge all the duties of office by reason of mental or physical disability.'"  28 U.S.C. § 351(a).  According to the Reply, the basis for its constitutional clarity is that it ties the definition of "disability" to whether a judge is "unable [to perform] all the duties of office," where disability is a term used "since the Founding" and thus presumed to have meaning based on "historical usage in the law," citing Arnett v. Kennedy, 416 U.S. 134, 160 (1974).  This argument is bolstered by the constitutional clarity with which the misconduct provision of the Act has been acknowledged, which is a term is "arguably less precise than the relatively concrete assessment" of being unable to perform judicial duties according to the Reply.  The Committee contends that "a vagueness challenge cannot succeed where the statutory standard is 'imprecise but comprehensible,' that is, where a conclusion whether the standard has been met 'may vary depending upon whom you ask,'" citing United States v. Bronstein, 849 F.3d 1101, 1107 (D.C. Cir. 2017) (citations omitted)" and faults Judge Newman for "never grappl[ing] with the vagueness standard or explain[ing] how the statute fails to meet that standard."  According to the Reply, a law is not constitutionally vague when it "'call[s] for the application of a qualitative standard to real-world conduct'" under Bronstein nor because a statute must be drafted to be "both general enough to take into account a variety of human conduct and sufficiently specific to provide fair warning," citing Arnett.

    The remainder of the Reply in this regard consists of the Judicial Council's contentions that Judge Newman has not rebutted its arguments in favor of the statute's constitutionally sufficient clarity.

    Finally, turning to Count VII of Judge Newman's complaint that the investigation provision of the Act is unconstitutionally vague, the Reply brief contends that Judge Newman has not asserted any reason "to doubt the sufficiency of [the standard that] "an investigation [is] as extensive as [a Judicial Council] considers necessary" (other than the implication that this is no standard at all, being entirely discretionary to the whims of the Court's Judicial Council).  Nevertheless, the Reply asserts that the constitutional clarity is "settled law," relying on other, seemingly inapposite jurisprudence (particularly Kincaid v. District of Columbia, 854 F.3d 721, 729 (2017), discussing United States v. Batchelder, 442 U.S. 114 (1979)).  "If the broad discretion over criminal charges and sentences at issue in those cases did not raise a constitutional problem, it follows that a provision merely granting investigative discretion cannot offend the Due Process Clause," the Reply asserts.

    It is fair to say that to the extent Judge Newman's brief focused on the particulars of her circumstances and the justification vel non of the Judicial Council's actions in these proceedings, the Committee's Reply focuses more generally on how the statute is constructed to address the issue of judicial misconduct or inability of a judge to satisfy judicial responsibilities.  Whether the case is dismissed or the remaining Counts are permitted to proceed will likely depend on how the District Court considers these different perspectives and their impact on Judge Newman's rights and interests, and whether they have been abridged.

  • By Joshua Rich

    USPTO Building FacadeAs discussed at length in a previous post on this blog (see "USPTO Proposed Rule Change to Terminal Disclaimer Practice"), the U.S. Patent and Trademark Office has proposed amending the form of terminal disclaimer to be used by patent applicants.  Specifically, it proposes requiring terminal disclaimers filed to obviate nonstatutory (or obviousness-type) double patenting to include an agreement that the patent will be enforceable only if no claim of any patent to which it is tied by terminal disclaimers has been found by a final decision of a court or the USPTO to be invalid or unenforceable.  There is a real problem that the USPTO is trying to solve, but it is not directly linked to nonstatutory double patenting.  Given that incomplete overlap between the problem and the proposed solution, it seems pretty clear that the proposed amended form of terminal disclaimer is the wrong tool for the job.

    Generally speaking, double patenting is a problem that arises when an applicant seeks more than one patent from a given chain.  It comes in two types:  statutory and nonstatutory.  Statutory double patenting arises when the applicant seeks more than one patent that claims the same invention; it is the equivalent of an anticipation rejection that is based on the applicant's own claims in another patent in the same chain.  It is termed statutory because it is based on the Patent Act's indication that "[w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title."[1]  Unlike the interpretation of some patent claims, courts have found that "a" there really means only one.  There is no solution to statutory double patenting, other than amending the claims of the rejected application.  Nonstatutory double patenting is the equivalent of obviousness for a single applicant.  It is a judicially-created doctrine that prevents an applicant from obtaining two patents that claim different, but too closely related inventions.  There is a solution to nonstatutory double patenting — terminal disclaimers.

    Terminal disclaimers align the terms of two or more related patents in order to solve two distinct problems.  The first problem is unfair extension of the exclusivity period beyond what could be obtained if the claims issued in a single patent.  Given the possibility of delayed issuance due to USPTO delay (a greater problem with pre-AIA patents, but still an issue) or other term adjustment, the two or more patents could have different terms that would add up to more than twenty years.  The terminal disclaimer solves that problem by shortening the term of a second patent to match the expiration of an earlier-issued patent.  The second problem is that the sale of one or more of the patents could lead to competitors being liable to two different patent owners for basically the same invention.  The purchaser could not have directly obtained the patent it seeks to assert because the claims would have been rejected as obvious over the unsold patent (or vice versa); it is just due to the quirk of the applicant being the same entity that allowed them to issue.  So a terminal disclaimer prevents alienation of the two patents from one another, to avoid the unfair possibility of "double jeopardy."

    More recently, a different type of patent gamesmanship has developed:  parties obtaining a raft of closely-related patents to cover every aspect of a product or process.  Whether in the form of a "patent thicket" protecting the owner's product or a patent assertion entity's patent horde, the broad portfolio allows the patent owner to pick and choose which of the patents to assert against numerous defendants.  The extent of the portfolio allows the owner to keep some patents in reserve, asserting only a portion of the portfolio against each defendant (sometimes the same patents, sometimes a different group).  By doing so, the patent owner can bludgeon potential licensees into a favorable settlement on the entire portfolio or run the risk of serial litigation.[2]  In the end, most defendants end up taking the easier route of settling, even if they believe the assertion of each patent in the portfolio would be tenuous, at best.

    It is this more recent problem that the new terminal disclaimer rule seeks to avoid.  As the USPTO phrased it, "This action is being taken to prevent multiple patents directed to obvious variants of an invention from potentially deterring competition and to promote innovation and competition by allowing a competitor to avoid enforcement of patents tied by one or more terminal disclaimers to another patent having a claim finally held unpatentable or invalid over prior art."[3]  It is true that the ability of patent owners to evergreen their patent litigation strategy by picking and choosing which patents to assert tamps down innovation.  But the proposed solution has lots of problems of its own.

    First, it is more likely than not that demanding a patent owner yield other patents and claims upon the invalidation of one claim is not a proper exercise of agency discretion in rulemaking.  The Patent Act is very clear in establishing that every claim of every patent is independently presumed valid.[4]  The proposed new terminal disclaimer turns that presumption on its head if even a single claim has been found invalid, either through post-grant proceedings or litigation.  While the USPTO has said it has taken (and is taking) the presumption of validity into consideration in the rulemaking process, it is hard to reconcile the rule with the statute.  And it is especially questionable in an era when the Supreme Court is looking for a reason to overrule Chevron deference to agency interpretation of statutes.[5]  So this whole process may end up a frolic and detour, with compelled conditions of terminal disclaimers that cannot be enforced.

    Second, the remedy of inability to assert patents later may come too much later to have real teeth.  The rule would prohibit assertion of other patents only after another claim has been finally adjudicated invalid or unenforceable.[6]  That means not only that the USPTO proceedings or district court litigation must be completed, but also that the appeal must be resolved.  But most litigation never goes to trial, let alone through appeal.  Instead, most parties settle, especially the parties threatened by patent assertion entities, who may be offered a far less costly deal if they settle before litigation begins.  So it may be many years from the first assertion of a patent in a terminal disclaimer family before any assertion of other patents is estopped.  That is especially true because patent owners' behavior may be altered by the incentives dictated by the terminal disclaimer, including potentially settling with a payment to the defendant to remove an invalidation from the books.

    Third, there may be very substantial unintended consequences from the proposed changes in prosecution, post-grant proceedings, and litigation.  In prosecution, there will be more incentive for parties anticipating litigation of the family to avoid terminal disclaimers.  They may seek to fight against nonstatutory double patenting rejections much harder (including through appeal) to avoid the potential prejudice of a terminal disclaimer.  That shifts a burden from litigating parties to patent examiners.  In post-grant proceedings, there will be an incentive for accused parties to find the broadest claim of the weakest patent in the family to challenge, even if the patent has not be asserted against them (or anyone).  The accused parties can then fight the battle on a different front of their choosing as a proxy for litigation.  This would turn the process on its head, shifting power from patent owners to accused parties, without much benefit for innovation.  Finally, in litigation, the behavior of patent owners is more likely to be bimodal — either they will want to settle early more often (and avoid potential invalidation of any patents) or they will fight tooth and nail to make sure the asserted claims are not invalidated.  In short, the proposed rule may cause changes in behavior, but they may not be the changes the USPTO is searching for.

    [1] 35 U.S.C. § 101 (emphasis added).

    [2] The proposed terminal disclaimer would give accused parties a stronger position than they could get even if they had won in litigation against the first invalid patent.  The Federal Circuit has held that a terminal disclaimer alone is not sufficient evidence to support the application of collateral estoppel in litigation of a second patent after the first has been found invalid.  XY, LLC v. Trans Ova Genetics LC, 968 F.3d 1323, 1334 (Fed. Cir. 2020).

    [3] 89 Fed. Reg. 40439 (Mar. 10, 2024).

    [4] 35 U.S.C. § 282.

    [5] Chevron deference, named after the Supreme Court's Chevron v. Natural Resources Defense Council decision, involves courts deferring to administrative agencies' reasonable interpretation of statutes within their area of expertise.  The Supreme Court has been asked to overrule Chevron deference in this term's Loper Bright Enterprises v. Raimondo and Relentless, Inc. v. Department of Commerce cases.  Regulations that appear to be based on unreasonable statutory interpretations will provide more fuel to the fire burning down deference to the USPTO and other administrative agencies.

    [6] The proposed rule also suggests that a statutory disclaimer would give rise to the prohibition on assertion of other patents, but a party knowing that to be the case would be unlikely to disclaim the claims — it makes more sense to fight on, instead of giving up the portfolio of related patents all at once.

  • By Andrew Velzen

    USPTO SealOn May 10, 2024, the U.S. Patent and Trademark Office announced a proposed rule change to terminal disclaimer practice.[1]  Unfortunately, the proposed change appears to further weaken issued patents in which terminal disclaimers have been filed and make obtaining robust patent protection more difficult and uncertain in the future.

    Present Nonstatutory Double Patenting / Terminal Disclaimer Practice

    One type of rejection a patent examiner can issue during pendency of a patent application is a nonstatutory double patenting rejection (sometimes called an "obviousness-type double patent rejection" or a "judicially created double patenting rejection").[2]  These rejections are "based on a judicially created doctrine grounded in public policy and which is primarily intended to prevent prolongation of the patent term by prohibiting claims in a second patent not patentably distinct from claims in a first patent" and traditionally arise when a subsequent asset (e.g., a patent application) has claims that are, in the patent examiner's eyes, obvious over a prior asset (e.g., a prior patent).[3]  Further, nonstatutory double patenting can be used after the fact (e.g., in litigation) as a grounds on which to invalidate a patent.

    One way of overcoming nonstatutory double patenting rejections is by filing a terminal disclaimer.[4]  The terminal disclaimer must include "a provision that any patent granted on that application . . . shall be enforceable only for . . . such period that said patent is commonly owned with the application or patent which formed the basis for the judicially created double patenting."[5]  In other words, both the application in which the terminal disclaimer is being filed and the reference patent must permanently remain commonly owned.  If they do not, any patent that issues from the application will essentially be rendered worthless.  This is typically referred to as the "common ownership requirement" for terminal disclaimers.[6]

    Proposed Change

    In the proposed rule change to 37 C.F.R. § 1.321, the USPTO is considering adding another requirement for a terminal disclaimer to be used to overcome nonstatutory double patenting rejections (in addition to the common ownership requirement).  Namely, under the proposed rule, the terminal disclaimer would also need to "include an agreement . . . that the patent in which the terminal disclaimer is filed, or any patent granted on an application in which a terminal disclaimer is filed, will be enforceable only if the patent is not tied and has never been tied directly or indirectly to a patent by one or more terminal disclaimers filed to obviate nonstatutory double patenting rejections in which:  any claim has been finally held unpatentable or invalid as anticipated or obvious by a Federal court in a civil action or by the USPTO . . . or a statutory disclaimer of a claim is filed after any challenge based on anticipation or obviousness to that claim has been made."[7]  According to the USPTO, the proposed rule is being made to "promote innovation and competition by allowing a competitor to avoid enforcement of patents tied by one or more terminal disclaimers to another patent having a claim . . . held unpatentable."[8]

    Essentially, what this means is that, if a patentee has multiple patents tied together by terminal disclaimers, a competitor would only need to successfully invalidate one claim in one of those patents based on prior art in order to render all of the patents invalid.  To highlight what a dramatic shift this represents, let's take an example.  Assume the following (which represents a relatively common occurrence in a traditional patent family involving multiple assets):

    1.  Patentee owns Patent X, Patent Y, and Patent Z;
    2. 
    During prosecution of Application Y (now Patent Y), the examiner gave a nonstatutory double patenting rejection over Patent X, so the patentee filed a terminal disclaimer in Application Y (now Patent Y) over Patent X; and
    3. 
    Likewise, during prosecution of Application Z (now Patent Z), the examiner gave a nonstatutory double patenting rejection over Patent Y, so the patentee filed a terminal disclaimer in Application Z (now Patent Z) over Patent Y.

    Under the current regime, a challenger would need to separately successfully challenge each of Patent X, Patent Y, and Patent Z (e.g., in district court or in an inter partes review or post-grant review before the Patent Trial and Appeal Board (PTAB)) in order to render each of Patent X, Patent Y, and Patent Z invalid.  Under the proposed rule change, though, the challenger would only need to successfully demonstrate that just one claim of Patent X is invalid over the prior art in order to automatically render all claims of Patent Y and Patent Z unenforceable.[9]  This is true even if the invalidated claim in Patent X is broader in all aspects than every claim in Patents Y and Z.

    Commentary

    This proposed change would substantially weaken a patent in which a terminal disclaimer is filed, since the patent's enforceability would be predicated entirely on the enforceability over the prior art of a separate patent over which the terminal disclaimer is filed.  Such a fundamental change to the patent system would be problematic.

    i)  No Quid Pro Quo

    First, this change lacks sufficient quid pro quo to be justified.  One impetus provided from the USPTO for this proposed change is that, presently, "multiple patents tied by terminal disclaimers that are directed to obvious variants of an invention could deter competition due to prohibitive cost of challenging each patent separately in litigation or administrative proceedings."[10]  While it is certainly true that, under the current terminal disclaimer regime, patents tied together by terminal disclaimers need to be challenged separately to render each of them invalid, it is also true that they need to be asserted separately.  In other words, demonstrating that a defendant has infringed one patent does not automatically lead to a finding of infringement over a related patent simply because there is a terminal disclaimer in place between the two patents.  Instead, the elements of the claims in each respective patent much be proved up separately against the putative infringer.  Under this proposed change, the paradigm would shift to being imbalanced.  While the burden would still be on the patentee to prove infringement in each and every patent separately, a purported infringer may only need to invalidate a single patent to automatically render an entire swath of patents unenforceable.

    Likewise, an issued patent only confers protection against infringement of what is claimed, but notably does not confer protection against infringement of all obvious variations of the claims.[11]  Instead, to obtain protection of an obvious variation, a patentee must pay to file, prosecute, and have issued another patent with a different set of claims (not to mention paying maintenance fees on the subsequent patent).  Why, then, should an opponent be able to invalidate a patent without also having to address each patent on its own terms (rather than simply challenging the weakest link in the chain)?  As pointed out by some commentary previously provided to the USPTO, this raises some real concerns regarding the patentee's due process rights.[12]

    ii)  The Issues are Compounded by Recent Changes in Jurisprudence and Other Proposed Changes by the USPTO

    Obviously, this proposed change does not occur in a vacuum, but is accompanied by everything else swirling around in the world of patent law.  Two other recent issues are also worth noting here.  First is the recent Federal Circuit decision in In re Cellect and second is the recent fee changes proposed by the USPTO.

    This blog has recently provided some insight on (and discussed the issues with) the In re Cellect decision.[13]  I also recently wrote a piece about practice steps that patentees / applicants can take to protect themselves against the fallout of the decision.[14]  To briefly summarize the primary result of that case, post In re Cellect, patentees can be put in the situation where patents with the same effective filing date can be used as prior art against one another for nonstatutory double patenting purposes based on the amount of patent term adjustment (PTA) awarded.  To be as safe as possible, and as I proposed in my post referenced above, patentees may want to consider filing proactive and/or bespoke terminal disclaimers.  This already seemed unduly onerous on the patentee (especially given that later-issued patent may result in invalidation of a prior-issued patent based solely on PTA, meaning that the patentee may need to retroactively file a terminal disclaimer in the prior-issued patent).

    However, this situation gets even worse when compounded with this proposed rule change from the USPTO.  Now, assuming two patents are even arguably obvious variations over one another, the patentee will be given a "Sophie's choice."  On one hand, the patentee can choose to file a terminal disclaimer of the patent with additional PTA over the patent with less PTA, which will protect them against the In re Cellect issue but will expose them to the vulnerabilities resulting from this proposed new terminal disclaimer rule (should the patent with less PTA be deemed invalid).  On the other hand, the patentee can refrain from filing a terminal disclaimer in the patent with additional PTA so as not to risk the vagaries of this new terminal disclaimer rule, but the patentee then will then risk invalidation based on PTA differences under In re Cellect should the patent with additional PTA be determined to be an obvious variant of the patent with less PTA.  This is effectively a lose-lose decision.

    Additionally, the USPTO recently proposed a set of fee changes.[15]  There are many changes proposed by the PTO therein, but I merely wish to highlight the proposed changes to the terminal disclaimer fee structure.  The fees for filing a terminal disclaimer are proposedly increasing by anywhere from 18% (if an applicant files a terminal disclaimer prior to a first action on the merits) to 724% (if an applicant files a terminal disclaimer in an issued patent).  This quite clearly indicates the USPTO's desire to encourage applicants / patentees to file terminal disclaimers proactively and early in prosecution.  It presents an interesting dichotomy that the USPTO is simultaneously encourage applicants to file terminal disclaimers early and often (with the proposed fee changes) while also severely increasing the risk associated with filing terminal disclaimers (with this proposed change). Further, even if an applicant ultimately does decide to file a terminal disclaimer, the applicant is clearly paying more (in terms of raw fees) and getting less (in terms of the value of the terminally disclaimed patent in light of the new risks invited by this rule change).

    iii)  Practical Implications

    Lastly, I'd like to highlight some practical implications that are created as a result of this new rule change.  As a result of the risks posed by terminally disclaimed patents under the new rule, applicants are likely to seek other ways of addressing nonstatutory double patenting rejections (rather than filing terminal disclaimers almost as a matter of course for expediency, as many applicants do currently).  The USPTO even provides some ways applicants might do so.[16]  The suggestions provided by the USPTO range from self-evident ("cancel[] or amend[] any conflicting claims in the application or in the other application containing the conflicting claims that formed the basis of the nonstatutory double patenting") to unhelpfully thermonuclear ("fil[e] a reissue application of the patent whose claims formed the basis of the nonstatutory double patenting in order to add canceled conflicting claims from the application into the reissue application, provided that the added claims do not introduce new matter into the reissue application").

    I think that the most realistic course of action an applicant will take will be to either amend their claims in a fashion that gets around the nonstatutory double patenting rejections or argue the nonstatutory double patenting rejection on the merits.  The former option is, at the very least, undesirable.  The latter option, on the other hand, puts applicant in the unenviable position of being forced to characterize their own reference on the record.  Ideally, under the new rule, examiners would put more effort into determining whether or not a nonstatutory double patenting rejection should apply (so that applicants aren't unnecessarily forced to make such a touch decision).  However, I have not seen any evidence from the USPTO indicating that they will adjust how they instruct examiners to identify and issue nonstatutory double patenting rejections as a result of this proposed change.

    Conclusion

    This proposed rule change strikes me as counterproductive to the exact purposes the USPTO is purporting to advance with it (namely, to "promote innovation").  The Federal Circuit, itself, has said that a terminal disclaimer does not give rise to the presumption that two patents are patentably indistinct.[17]  Given all this, it seems like an incredibly bold and unnecessary step for the USPTO to promulgate this rule change.  Between the issues inherent with this proposed rule change and the result in In re Cellect, it may be time for Congress (rather than the judicial branch and the executive branch) to weigh-in substantively on nonstatutory double patenting rejections and terminal disclaimer practice.

    Comments on this proposed rule change are being accepted by the USPTO until July 9, 2024.[18]  It will certainly be interesting to see how the public responds and what the USPTO does about it.

    [1] Full text of the proposed rule change can be found at https://www.federalregister.gov/public-inspection/2024-10166/terminal-disclaimer-practice-to-obviate-nonstatutory-double-patenting.

    [2] See the following for a full discussion of nonstatutory double patenting rejections — https://www.uspto.gov/web/offices/pac/mpep/s804.html.

    [3] M.P.E.P. § 804

    [4] 37 C.F.R. § 1.321

    [5] 37 C.F.R. § 1.321(c)(3)

    [6] The "common ownership requirement" is obviously in addition to the inherent effect of a terminal disclaimer that limits any term of the disclaimed patent that would extend beyond the term of the patent over which it is disclaimed.

    [7] https://www.federalregister.gov/documents/2024/05/10/2024-10166/terminal-disclaimer-practice-to-obviate-nonstatutory-double-patenting.  In addition to the substantive changes, it might be of interest to some that the USPTO is also proposing changing the C.F.R.'s wording from the phrase "judicially created double patenting" to "nonstatutory double patenting."  This change, at least, is a positive in my view, as it brings the terminology of the C.F.R. into better conformance with the terminology of the M.P.E.P.

    [8] https://www.federalregister.gov/documents/2024/05/10/2024-10166/terminal-disclaimer-practice-to-obviate-nonstatutory-double-patenting

    [9] This example of cascading unenforceability is similar to Example 2 discussed in the proposed rule change.  It illustrates so-called "direct tying" under the proposed rule change between Patent X and Patent Y and "indirect tying" under the proposed rule change between Patent X and Patent Z.  Note, however, that the rendering of unenforceability remains unidirectional, even under the proposed new rule.  In other words, under this hypothetical, it wouldn't be sufficient to demonstrate that Patent Z is invalid in order to render Patent X or Patent Y unenforceable.  See, e.g., https://www.federalregister.gov/documents/2024/05/10/2024-10166/terminal-disclaimer-practice-to-obviate-nonstatutory-double-patenting ("As is the case under current practice, a terminal disclaimer under the proposed rule would be unidirectional, encumbering only the patent with the terminal disclaimer and not the conflicting patent.")

    [10] https://www.federalregister.gov/documents/2024/05/10/2024-10166/terminal-disclaimer-practice-to-obviate-nonstatutory-double-patenting

    [11] A patentee does ostensibly get protection of a slightly broader range of things than is literally described in the claims under the Doctrine of Equivalents.  See, e.g., Warner-Jenkinson Co. v. Hilton Davis Chemical Co. (1997).  However, the coverage under Doctrine of Equivalents is certainly not so broad as to cover all obvious variants (and, instead, only covers "insubstantial" differences relative to the claimed invention).

    [12] See Request for Comments on USPTO Initiatives To Ensure the Robustness and Reliability of Patent Rights, 87 FR 60130 (October 4, 2022); https://www.federalregister.gov/documents/2024/05/10/2024-10166/terminal-disclaimer-practice-to-obviate-nonstatutory-double-patenting.

    [13] https://www.patentdocs.org/2023/10/overcoming-the-consequences-of-in-re-cellect.html

    [14] https://www.mbhb.com/intelligence/snippets/living-with-cellect-three-best-practices/

    [15] https://www.federalregister.gov/documents/2024/04/03/2024-06250/setting-and-adjusting-patent-fees-during-fiscal-year-2025

    [16] https://www.federalregister.gov/documents/2024/05/10/2024-10166/terminal-disclaimer-practice-to-obviate-nonstatutory-double-patenting

    [17] SimpleAir, Inc. v. Google LLC (Fed. Cir. 2018).

    [18] Comments may be submitted at https://www.regulations.gov/.

  • By Michael Borella and Yuri Levin-Schwartz* —

    The recent rise in generative artificial intelligence (AI) models has granted powerful tools to the public that enable the creation of realistic, yet fake, images, sounds, and videos.  Though more than six months remain until the U.S. general election in November, these tools have already been used to create fake calls from President Biden and fake images of President Trump.

    Motivated by the impact that such tools could have on an election, at least ten states have enacted statutes governing the use of AI models in electioneering.  These states are California, Indiana, Michigan, Minnesota, New Mexico, Oregon, Texas, Utah, Washington, and Wisconsin (some of these statutes do not specifically mention or imply AI but are written broadly enough to cover use of AI).  Moreover, four states, Michigan (bill 1, bill 2), Minnesota, New York, and Washington, recently enacted further statutes governing the use of synthetic media in elections.**

    The statutes have a variety of proscriptions, ranging from requiring the disclosure of the use of AI models to creating the possibility of injunctions and criminal charges for the deceitful use of such models.  While potentially powerful, many of these statutes require a showing for deceitful intent.  Such a showing may prove difficult to establish and it may hinder effective use of these statutes to regulate AI-generated content especially if such content is released shortly before an election.

    Generally, state statutes do not call for an outright ban on the use of AI models to generate images, sounds, or videos relating to candidates or political parties.  However, nearly all statues require some form of disclosure to indicate that the content was generated using AI.  An example is California Election Code § 20010, which prohibits the distribution of "materially deceptive audio or visual media . . . of [a] candidate with the intent to injure the candidate's reputation or to deceive a voter into voting for or against the candidate."  This prohibition does not apply if the audio or visual media includes a disclosure, which states: "This [Image/Video/Audio] has been manipulated."  Such a disclosure must "appear in a size that is easily readable by the average viewer" or "clearly spoken manner and in a pitch that can be easily heard by the average listener."  Such disclosures are crucial, especially as AI-generated content becomes increasingly common and humans are less able to differentiate real images from those generated using AI.

    Though each state's statute is different, a common trend across these statutes is the creation of disincentives for the misuse of AI-generated content in elections.  Three states, Michigan, Minnesota, and Texas, establish criminal penalties for the misuse of AI-generated content in the context of an election.  One such example is Texas Election Code Ann. § 255.004, which makes it a Class A misdemeanor to create and cause to be published or distributed "a deep fake video," defined as "a video, created with the intent to deceive, that appears to depict a real person performing an action that did not occur in reality."  The punishment for committing a Class A misdemeanor is a fine not exceeding $4,000 and/or a jail term not exceeding a year.

    As noted, many statutes addressing the use of AI in elections has some form of intent requirement, generally an intent to deceive or affect an election.  Such a requirement has the advantage of limiting liability in cases where the use of AI was not intended to harm an individual or affect an election.  However, such a threshold can hinder effective use of injunctive relief, especially when content is created shortly before an election.  Interestingly, neither New Mexico's statue (N.M. Stat. Ann. § 1-19-26.4) nor Indiana's statue (Ind. Code § 3-9-8-6) require intent for liability.  Thus, both statutes regard misuse of AI during an election as a strict liability offense.  But like other states, both allow the publication of election content generated using AI if the content has a disclosure acknowledging the use of AI in the production of such content.

    So far, a relatively small number of states have taken steps to address potential misuse of AI during the upcoming 2024 election.  These statutes could help curb misuse of AI in the generation of misleading video, pictorial, and audio content — but only within those states.  Further, only two of these states (Michigan and Wisconsin) are considered "swing states" that could end up deciding the election.  Notably, none of these statutes would punish the developers of AI models, thus implicitly acknowledging the dual use nature of these models.

    * Yuri Levin-Schwartz, Ph.D., is a law clerk at MBHB.

    ** For more information on state statutes governing the use of AI in elections, see "Artificial Intelligence (AI) in Elections and Campaigns".

  • By Kevin E. Noonan –

    Bluewhale877The "genome revolution" over the past 30 years has resulted in the elucidation of several species, both domesticated (see, e.g., "The Genetic Basis of Coat Variation in Dogs"; "Further and More Detailed Study of Domestic Cat Genome"; "Chicken Origins Established (But Philosophical Questions Remain)"; "Rose Genome Reveals Its Exquisite Complexities") and not ("Red Fox Genome Sheds Light on Domesticated Dogs (and Maybe Humans)"; "Lowland Gorilla Genome Sequenced"; "Giraffe Genome Reveals Relevant Adaptations"; "Genome Structure of the American Cockroach").  Recently, a group of researchers from the U.S., Canada, Europe, and the United Kingdom published the results of their studies with the blue whale, Balaenoptera musculus, which while being "the largest animal to have ever existed, reaching up to 110 feet in length and weighing 330,000 pounds" does not have the largest eukaryotic genome (at 2.7 billion base pairs (Gbps), compared with Paris japonica at 149 Gbps and the Australian lungfish at 43 Gbps); see Bukhman et al., 2024, A high-quality blue whale genome, 1 segmental duplications, and historical  demography, Molec. Biol. Evol. Vol. 41, No. 3; https://doi.org/10.1093/molbev/msae036).

    The paper acknowledges the existence of four subspecies of blue whales that are currently recognized:  three found in the Southern Hemisphere and northern Indian Ocean, and the fourth (an individual from which produced the "high-quality" genomic information they disclose*) that includes blue whales in the North Atlantic and North Pacific.  The results presented here suggest that these two populations began to diverge 100–200,000 years ago, and became "completely genetically isolated" from one another at the time of the last interglacial period (about 20,000 years ago).

    One of the goals of the research is related to the observation that large animals seem to have developed mechanisms to resist cancer (a phenomenon termed Peto's Paradox).  Previous genome sequencing of large animals had revealed mutations and duplications of tumor suppressor genes and genes involved in DNA repair and apoptosis, which may account for the observed biology (large mammals, which by having more cells that would suggest higher susceptibility to cancer).  Previous studies had also identified segmental duplications (SDs) associated with longevity and increased body size in cetaceans and elephants and duplicated genes and gene families in cetacean genomes using short-read and long-read sequencing methods.

    Here, the assembled blue whale genomic sequences obtained by these researchers could be assigned to 23 chromosomal-level scaffolds from the 21 whale autosomes plus the X and Y chromosomes (the sample was a male, although sequencing of the Y chromosome was incomplete).  Comparative analysis was performed between the blue whale genome and the vaquita (Phocoena sinus), bottlenose dolphin (Tursiops trunca), and cattle (Bos taurus) genomes which are evolutionarily related as members of the placental mammal Order Artiodactyla.

    The assembly showed both a high level of completeness and revealed gene duplications and expansions in the blue whale genome.  This research revealed an evolutionarily recent burst in segmented duplications (SDs) that were correlated with body size in cetaceans.  SDs detected in the blue whale genome are "gene rich, amounting to a roughly 7.1-fold burst in gene duplications relative to vaquita and dolphin, and 3.0-fold relative to cattle."  These researchers detected 234 duplicated genes in the blue whale, 167 in the vaquita, 211 in dolphin, and 205 in cattle.  The distribution of amplified genes showed that "the ten most highly amplified genes account[ed] for 331 gene copies out of 700 (47%) total duplicated genes."  The blue whale sample showed 46 genes having more than 4 copies, compared with 9 in dolphin, 8 in cattle, and 6 in vaquita.  It had been shown in previous studies that in cattle there are 163 loci associated with body size, and these researchers found 52 corresponding loci in blue whales and 53 such loci vaquita. In particular comparisons between blue whale and vaquita were identified 133 duplicated genes of potential interest that included KCNMB1, which contained ancient (>20 Mya) duplication events.  Other genes detected as duplications in the whale genome include ones related to longevity (MT1X), body size (CHRNB1, DPEP2), development (FZD5, CDK20), cancer (C2orf78, FZD5, DDX24, NCAM1, MT1X, XRCC1, CDK20), obesity and diabetes (DPEP2), and the immune system (NCAM1), with certain of them having been greatly amplified (such as XRCC1, CDK20, and CHRNB1x).  A comparison between the genomic regions encoding XRCC1 in blue whale was shown in this figure, illustrating genomic rearrangement in whale not found in vaquita:

    Image 1
    A specific gene found to be amplified in blue whale was Insulin-like growth actor 1 (IGF-1), which has been associated with large body size in dogs (see "From Toy Poodle to Rottweiler: Why Is Fido So Small (or Large)?").  Single nucleotide polymorphism (SNP) analysis was performed on a specific SNP associated with size variation and showed a lack of the variant responsible for large (CA) and small (CG) size, sharing with humans, artiodactyls and other mammals the same sequence (AG) in this SNP.  Accordingly, multiple alignment of IGF-1 sequences were performed on 11 cetacean and 18 land artiodactyl species, wherein the 11 cetaceans fell into three phylogenetic clades illustrated by this phylogenetic tree:

    Image 2
    wherein the first clade comprises large baleen whales, blue (Balaenoptera musculus) and minke (B. acutorostrata); second, a giant toothed whale, the sperm whale Physeter catodon; and third, smaller toothed whales, including orca (Orcinus orca), dolphins, and porpoises.  These studies revealed that three large whales (blue, minke, and sperm), have a different allele from all other artiodactyls found at two sites in the intergenic region upstream of the IGF-1 gene, four in the second intron, and one in the third or fourth intron, depending on the IGF1 isoform.  The orca was found to have the same allele as its smaller relatives at these sites.  Also found where sites where the four largest whales (blue, minke, sperm) and orca, have a different nucleotide compared to all smaller cetaceans, with there being four such sites in the second intron and one in the third intron.  The authors suggest that the large whales have the ancestral allele, while the small ones have evolved an alternative and note that the orca, while being more closely related to smaller dolphins, has the allele characteristic of baleen and sperm whales.

    The paper also discusses their "historical demography analysis that suggested a population division between Pacific and Atlantic blue whales."  These population metrics were substantially the same between the Pacific and Atlantic populations of blue whale until the end of the Saalian ice age about 125 million years ago.  The Atlantic population then showed a slight increase over the Pacific population until the last glacial maximum (LGM) about 20,000 years ago, according to the paper, when both populations decreased.  Pacific and Atlantic blue whale populations were found to be highly heterozygous and genetically isolated since the last interglacial period, with blue whales in the North Atlantic and eastern North Pacific beginning to diverge around 100-200,000 years ago.

    "Runs of homozygosity analysis" revealed that since that time there has been a low level of inbreeding in the blue whale population, the paper explaining that "[r]uns of homozygosity (ROH) are indicative for the frequency and relative timing of inbreeding events and were frequently used to assess the impact of inbreeding on different mammalian and cetacean populations."  The data obtained showed 108 runs that were 500 kb or longer in both Pacific and Atlantic populations, and that over 70% of these ROH were shorter than 1 Mb, which indicated that "most ROH were probably fragmented over time by frequent outcrossing."  According to the paper, the "high heterozygosity and short runs of homozygosity in the blue whale genome suggest a large and outbred population in the Northern Pacific."

    The paper concludes by asserting that "[a] major finding of this work is the presence of large copy number expansions of a number of genes in the blue whale, while relatively few such expansions are observed in vaquita, bottlenose dolphin, and cattle [which] expansions [in whales] are recent in evolutionary time" and "the assembly will serve as a valuable resource to the scientific community, enabling future comparative genomics studies to further our understanding of large animal longevity and associated resistance to cancer, and helping conserve this magnificent species."

    For those interested in methodology used by these researchers the paper discloses the following:

    * Our assembly has been annotated by NCBI.  Additionally, we annotated both primary and alternate pseudohaplotype by projecting human and mouse genes using TOGA (Tool to infer Orthologs from Genome Alignments).  We also predicted GO terms for all protein coding genes identified by the NCBI Eukaryotic Genome Annotation Pipeline using Phylo-PFP.

  • By Andrew Velzen

    On January 19, 2024, Palworld launched into early access on Xbox and Windows.  To say it was an overnight success is an understatement.  By only a month in, Palworld had been played by over 25 million players.[1]  To put this in perspective, monumental success stories like The Legend of Zelda: Tears of the Kingdom and Hogwarts Legacy (both released in 2023) have sold in the ballpark of 20-25 million copies.[2]  It is not surprising that Palworld's meteoric rise has generated a lot of buzz in the industry.

    What is Palworld

    Palworld is a survival game developed and published by Pocket Pair that is "set in an open world populated with animal-like creatures called 'Pals,' which players can battle and capture to use for base building, traversal, and combat.  Players may also assign the 'Pals' to bases where they will automatically complete tasks for the player.  Palworld can be played either solo or online with up to 32 players on one server."[3]  Most saliently for this discussion, though, is the fact that the "Pals" bear a not-so-subtle resemblance to Pokémon (e.g., in name and/or likeness).[4]  As just one of countless examples, compare the following image of the Pal Grizzbolt (left) with the Pokémon Electabuzz (right):[5]

    Image 1
    In fact, given the visual overlap, gamers have started colloquially referring to Palworld as "Pokémon with Guns."

    Accusations of Infringement

    Given the striking resemblance, it isn't surprising that many in the industry have wondered whether any of Game Freak Inc. / The Pokémon Company / Nintendo Co., Ltd. (collectively referred to herein as the "Pokémon Owners") would initiate action for copyright infringement against Pocket Pair, especially given Nintendo's notoriously litigious reputation.[6],[7]  Interestingly, Pocket Pair has a history of making games that appear, at least facially, to be clones of other games.[8]  As far as I'm aware, none of the Pokémon Owners have yet to take any legal action against Palworld.  That isn't to say that the Pokémon Owners aren't seriously considering such action, though.  In fact, regarding Palworld, The Pokémon Company issued the following statement:[9]

    We have received many inquiries regarding another company's game released in January 2024.  We have not granted any permission for the use of Pokémon intellectual property or assets in that game.  We intend to investigate and take appropriate measures to address any acts that infringe on intellectual property rights related to the Pokémon.  We will continue to cherish and nurture each and every Pokémon and its world, and work to bring the world together through Pokémon in the future.

    I have heard 3 main allegations levied regarding the creation of the Pals vis-a-vis Pokémon.  Namely, that Pocket Pair: (a) generally copied many concepts of Pokémon in a creatively bankrupt fashion, (b) obtained three-dimensional (3D) models of Pokémon and only made slight modifications to those models before pushing them out the door, and/or (c) trained a generative artificial intelligence (AI) using 3D models of Pokémon and then had that AI produce 3D models for Pals.[10]  To my knowledge, there has been no publicly accessible discovery thus far, so we can't, with absolute confidence, ascertain which of these three allegations (if any) are true.  Still, I plan to discuss the potential merits of a copyright infringement suit in the United States against Pocket Pair under each of these hypothetical copying regimes.[11]

    What Would the Complaint Allege?

    A successful copyright infringement suit requires that plaintiff has a registered copyright on an underlying copyrightable work (or an exclusive license thereto), that defendant infringed on an exclusive right conferred by the copyright (without a license), and that no defenses apply (e.g., there is no fair use defense).  The primary questions in a hypothetical Pokémon Owners v. Pocket Pair case are: (i) which aspects of Pokémon are covered by the Pokémon Owners' copyrights (i.e., which aspects are copyrightable) and (ii) would Pocket Pair have a reasonable fair use defense.  I will analyze both of these questions for each of the three sets of potential facts.

    First – What if Pocket Pair simply copied some or most of the general concepts that make Pokémon successful?

    As a first consideration, does the fact that Palworld is a game that involves catching monsters and using them in combat mean that Pocket Pair has infringed a copyright?  I think most people would inherently understand that this fact, taken alone, would be insufficient to constitute copyright infringement, but let's briefly discuss why.

    As a general rule, "ideas" aren't copyrightable (rather, only expressions are).  This is, unsurprisingly, typically referred to as the "idea-expression dichotomy," and is codified in 17 U.S.C. § 102(b).[12]  One tenant of the idea-expression dichotomy is that certain concepts are so common / ubiquitous to a given medium or genre that such concepts are not copyrightable (these concepts are sometimes referred to as scènes-à-faire).  In the video game world, this could include things like user interface menus or combat or character creation, but can extend even further to the entire underlying genre of a game (e.g., the general concept of a "fighting game" is not protectable by copyright).  I won't get into it here, but for a good illustration of where the line is between what is a scène-à-faire and what is protectable by copyright, contrasting Atari v. Amusement World with Tetris v. Xio is instructive.[13]

    Here, the idea of monsters fighting with one another or against a player is probably not something that could be covered by a copyright.  For example, the concept of monsters that take forms that are subtly or directly inspired by various animals, people, or forces of nature (as many Pokémon are), is something that has been present in the culture of Japan for thousands of years in the form of the Yōkai.[14]  As a specific example in the context of Pokémon / Palworld, the general concept of a fox (kitsune) with some magical powers is well-known, so it cannot be the subject of a copyright.  In fact, both games include multiple fox creatures (one of the Pals even being named "kitsun"):[15]

    Image 2
    Given all this, it is unsurprising that, historically, the Pokémon Owners have not pursued litigation against games that are far more similar to Pokémon (at least in terms of gameplay) than Palworld is (e.g., Digimon World, Temtem, etc.).[16]

    Second – What if Pocket Pair copied underlying Pokémon models?

    So, while the general concepts employed in Pokémon aren't likely protectable by copyrights, what about the 3D character models, themselves?  While it is only conjecture at this point whether actual Pokémon models were copied in the production of Palworld, there are some in the industry that have promulgated what they believe to be strong evidence of such copying.[17]  This narrative has unsurprisingly been opposed by Pocket Pair.[18]  Regardless, for the sake of argument, let's assume that Pocket Pair did in fact have access to the underlying 3D Pokémon models and only made minor tweaks (e.g., slight modifications to limb-shape, face-shape, hair-shape, or hair color; remeshing; reskinning; modifying relative proportions; etc.) to arrive at the Palworld models.  Would this be copyright infringement?

    3D models are protectable by copyright, so long as the 3D model isn't merely an exact one-to-one digital rendering of something that exists in the physical world (i.e., so long as some originality / creativity was present in the development of the model).[19]  Further, to my knowledge, no Pokémon are exact replicas of any naturally occurring creature (i.e., while there may be cow Pokémon, a 3D scan of an actual bovine was not merely replicated to generate Miltank).[20]  Given this, the 3D models of Pokémon could be subject to copyright protection.  Thus, if the 3D models of Pokémon were directly imported into Palworld, the Pokémon Owners would have a strong case for infringement.  In fact, this isn't so far off from something that almost happened (not as a result of the actions of Pocket Pair, but as a result of the actions of a Palworld modder).  The modder uploaded a YouTube video and a tweet that previewed a mod that imported Pokémon directly into Palworld.[21]  Nintendo, unsurprisingly, swiftly issued a Digital Millennium Copyright Act (DMCA) strike against both the video and the tweet.  Even further, in an abundance of caution, the popular modding site Nexus Mods preemptively banned the uploading of any Palworld mods related to Pokémon.[22]

    So, we know that it would not be okay for Pocket Pair to directly import / use Pokémon models in Palworld, but, assuming Pocket Pair had lawful access to the Pokémon models (e.g., could reverse engineer them in a lawful way), would it be okay if Pocket Pair modified the models and put them into Palworld.  This is where the typical lawyer answer of "it depends" comes into play.

    One of the rights that a copyright holder has (e.g., that the Pokémon Owners have here in relation to the 3D Pokémon models) is the right to prepare derivative works.[23]  The U.S. Copyright Office lists the right to prepare derivative works as including "[a] revision of a website" and "[a] new version of an existing computer program."[24]  As such, the Pokémon Owners own the right to prepare a "new version" of the original 3D Pokémon models.

    This right only protects the Pokémon Owners to the extent that a resulting 3D model is derivative of the original work, though.  In some cases, the resulting work is so transformative that the producer of the resulting work has a fair use defense.  Hence, the question here becomes whether the modifications to the underlying Pokémon models is sufficiently transformative (and, therefore, subject to the fair use defense).

    In order to determine what is and is not transformative, we can look to the 4 fair use factors: (i) the purpose and character of the use, including whether such use is of a commercial nature or is for nonprofit educational purposes; (ii) the nature of the copyrighted work; (iii) the amount and substantiality of the portion used in relation to the copyright work as a whole; and (iv) the effect of the use upon the potential market for or value of the copyrighted work.

    The above factors are obviously debatable and fact-specific.  However, if the Palworld models are, in fact, only minor modifications to the Pokémon models, I believe at least 3 of the 4 factors would weigh against a finding of fair use.  Under these assumed facts, the following considerations are likely relevant to the factors recited above:

    i.  The Palworld models are being used commercially, in bad faith (e.g., without permission from the Pokémon Owners and without public admission), and for essentially the same purpose as the Pokémon models (weighing against a finding of fair use);

    ii.  The creation of the original Pokémon models was a highly creative endeavor (weighing against a finding of fair use);

    iii.  Only a few dozen or so of the plethora of Pokémon models have been replicated in Palworld (weighing in favor of a finding of fair use); and

    iv.  Palworld and Pokémon are both video games competing in the same market for gamers to purchase their games and, even if they have yet to do so, the Pokémon Owners could make a similar game to Palworld (hence, it was a market that the Pokémon Owners would've been able to exploit) (weighing against a finding of fair use).

    One final note regarding fair use.  One of the stronger ways to demonstrate fair use is to show that a work is a parody.  One could clearly argue that "Pokémon with Guns" is a parody of Pokémon.  Palworld includes many aspects that are not only opposite of Pokémon, but clearly meant to poke fun at Pokémon.  For example, rather than petting a Pokémon, you can butcher a Pal or rather than an animal/trainer relationship between players and Pokémon, there can be a master/slave relationship between players and Pals.[25]  Thus, there is at least a colorable argument that Palworld exists to ridicule some of the underlying tenants of Pokémon.[26]

    Still, in my view, the primary purpose of Palworld is not to make fun of Pokémon, but to be a commercial success in its own right by exploiting the exact same market that the Pokémon Owners could, themselves, exploit.  Hence, in my view, it would be difficult for Pocket Pair to argue that Palworld is a parody (especially in light of all the fair use factors considered above).

    Third – What if they used the models to train an AI, though?

    Under the third set of potential facts, Pocket Pair is assumed to have taken the Pokémon models, trained a generative AI (genAI) using the Pokémon models, and then used the genAI to produce the Pal models (e.g., by employing a generative adversarial network (GAN)).  This third set of circumstances is perhaps the most interesting (as the first set of circumstances likely does not constitute copyright infringement and the second set of circumstances likely does constitute copyright infringement).

    The foundational question here is clearly "is it copyright infringement to use copyrighted material to train a generative AI?" Fortunately, to answer this question, we can look to a growing number of cases concerning this exact issue.  For instance, many developers of large language models (LLMs) are being sued for using copyrighted material to train their LLMs.[27]  Unfortunately, though, none of these cases have yet been decided, so we aren't sure how U.S. courts feel about this (which is exacerbated by the fact that none of the cases have percolated above the district court level either, and this issue will likely be an issue that appeals courts, or even the U.S. Supreme Court, will need to weigh-in on).

    Still, we can compare / contrast the Palworld saga with one of the AI cases; let's use the one with perhaps the highest notoriety — New York Times v. Microsoft and OpenAI.  In that case, the New York Times has alleged that OpenAI / Microsoft's genAIs "rely on large-language models that were built by copying and using millions of The Times's copyrighted news articles, in-depth investigations, opinion pieces, reviews, how-to guides, and more" and that "the outputs of the defendants' GenAI models compete with and closely mimic the inputs used to train them, copying Times works for that purpose is not fair use."[28]  Whether such use does, in fact, constitute fair use (contrary to the New York Times's assertion) is a judgment call.  From one point of view, the LLM is ingesting a bunch of data (with the Times's articles being just a portion of it) and then generating something wholly new based on a future prompt.  This is arguably not unlike the way in which a musician, after having listened to copious amounts of other songs from other artists, then takes inspiration from those songs and writes their own new song. Almost always, this new song is validly copyright-eligible.

    The odd case where the new song is not copyright-eligible (and may, in fact, constitute copyright infringement) is when the new song is too similar to an older song.  For example, Pharrell Williams, Robin Thicke, and Clifford Joseph Harris (T.I.) lost a case against Bridgeport Music regarding the song "Blurred Lines" in view of the previous Marvin Gaye song "Got to Give It Up" since, in the eyes (ears?) of the jury, there was sufficient overlap between the i) signature phrase ii) hooks iii) bass lines iv) harmonic structures, and v) keyboard chords of the two songs to constitute copyright infringement.[29]

    If I'm prognosticating by analogizing to the case of LLMs trained on copyrighted material, I'm inclined to guess that courts will think that it's more of a question of the output, rather than the inputs (i.e., more a result of what the models spit out, rather than how they're trained).  Said another way, you as an individual have a right to read an article you paid for.  You can also save a PDF copy of the article onto your computer for your own future reading.  Even further, you could perform processing (e.g., optical character recognition (OCR)) on that article if you like.  However, you cannot forward that article on to 10 other people.  Likewise, it stands to reason that you can use an article you purchased to train your own LLM, so long as the LLM doesn't output copyrighted material directly to third parties.  Hence, if an LLM trained on a number of New York Times's articles responds to a query with an answer based on information it has gathered from those articles, that's probably fine.  For example, if an LLM is prompted with "provide me with a brief summary of the Red Sox / Yankees game from October 20, 2004," and, based on information ingested from the New York Times's articles, the LLM spits out "the Red Sox hit 4 home runs to beat the Yankees 10-3 in game 7, capping off a monumental comeback after being down 3 games to 0 entering game 4 of the ALCS," I don't think there would be a problem (as the information from the article would be sufficiently "transformed" so as to constitute fair use).[30]  If, however, when prompted with "provide me with a copy of the first article on the front page of New York Times on October 21, 2004," the LLM spits out a verbatim copy of the article, there is a much more colorable argument that copyright infringement has occurred (especially if the New York Times's articles constituted a large plurality, much less a majority, of the training data).

    Assuming many of these cases turn on what the LLM will and will not output (and that's a big assumption, as judges can be about as predictable as a random number generator), we can return to Palworld.  Assuming the Pal models were generated by an AI trained on Pokémon models, and we were to compare the complete set of Pal models to the complete set of Pokémon models, there isn't altogether that much overlap.  Only some of the Pal models show striking overlap with Pokémon models (and certainly fewer than 50% of them) and most Pokémon models have no clear Palworld analog whatsoever.  Further, even for the models that do overlap, the genAI has clearly at least tweaked some combination of color, meshing, size, shape, etc.  Given this, I would think this situation is more akin to someone listening to all of Taylor Swift's albums and writing a song in Taylor's pop style that has lyrics about the same general topics as Taylor's songs (i.e., likely fair use), rather than someone listening to The Tortured Poet's Department and releasing an album where half the songs are direct copies of those in Taylor's album (i.e., likely not fair use).

    Given the above, I find it unlikely that, if a genAI were trained (at least partially) on the Pokémon models and used to create each of the Palworld models, copyright infringement has occurred.

    Don't forget about trade secrets?

    As just one final thought (and something I haven't seen discussed much in the Palworld discourse), regardless of whether Palworld constitutes copyright infringement, if the Palworld 3D models were based on actual Pokémon 3D models (e.g., regardless of whether they were subsequently used to train a genAI or tweaked by a human), the Pokémon Owners may have a cause of action based on trade secret protections.  For example, if Pocket Pair illegally accessed a Pokémon Owner's server to obtain the underlying 3D model and/or if a former or current employee of the Pokémon Owners improperly provided the 3D model to Pocket Pair, such actions could constitute a misappropriation of trade secrets.  Hence, Pocket Pair profiting from them would be improper (and Pocket Pair could be liable for damages).[31]  That is, of course, assuming there was no reasonable way to reverse engineer the Pokémon 3D models without improper means (e.g., without violating Pokémon terms of service).  Given the above, in addition to or instead of a copyright infringement action, the Pokémon Owners could succeed in a trade secrets suit against Palworld if Pocket Pair stole or otherwise improperly obtained the Pokémon models.

    Conclusion

    It's obviously debatable whether the Pokemon Owners would succeed in a suit against Pocket Pair over Palworld.  It would come down to the facts regarding whether and how the models for the Pals were generated (and, if a lack of direct evidence were present, what a jury might think of circumstantial evidence of copying).  It becomes even more convoluted if each of the three factual situations posited above occurred in conjunction with one another (rather than only one of the three occurring alone). Further, given the success of Palworld, I doubt that Pocket Pair would have the stomach for full on litigation against the Pokémon Owners (i.e., would settle before anything progressed very far).

    This is 100% conjecture, but if I were a psychic Pokémon casting Future Sight, my guess would be that the Pokémon Owners will let sleeping dogs lie and decline to pursue this in any way.  The only exception, in my view, would be if the Pokémon Owners have some smoking gun regarding illicit access to their 3D models.  In such a case, I would assume the Pokémon Owners would send a cease and desist to Pocket Pair threatening litigation and that Pocket Pair would respond by removing (or heavily modifying the character models of) the Pals that were created as a direct result of the improperly obtained Pokémon models.

    As Professor Oak says, this "tale of grand adventure is about to unfold."[32]

    [1] https://twitter.com/Palworld_EN/status/1760682105171062876

    [2] https://www.forbes.com/sites/paultassi/2024/02/06/hogwarts-legacy-barely-holds-off-tears-of-the-kingdom-for-most-sales-of-2023/?sh=46beea2f128a

    [3] https://en.wikipedia.org/wiki/Palworld

    [4] On that note, if you're looking for some late '90s nostalgia and some music to read by, might I recommend – https://www.youtube.com/watch?v=rg6CiPI6h2g

    [5] https://gamerant.com/palworld-electric-element-pals-pokemon-counterparts-similarity-explained-grizzbolt-electabuzz/. Plenty of other articles have been written enumerating the Pals that resemble Pokémon counterparts, as well. See also, https://www.ign.com/articles/palworld-vs-pokmon-comparison-just-how-similar-are-the-designs, https://clutchpoints.com/all-the-pokemon-look-alikes-in-palworld, https://www.sportskeeda.com/mmo/5-palworld-pal-designs-similar-popular-pokemon, https://gamerant.com/palworld-pokemon-controversy-stolen-designs-every-pal-similarity-explained/.

    [6] https://www.ign.com/articles/as-palworld-blows-up-could-nintendo-successfully-sue-the-controversial-pokemon-with-guns-game 

    [7] https://www.thegamer.com/a-snapshot-of-nintendos-convoluted-legal-history/  

    [8] In 2020, Pocket Pair released a survival game called Craftopia that had a very similar aesthetic to Nintendo's The Legend of Zelda: The Breath of the Wild (https://www.gameinformer.com/2024/02/22/what-is-palworld-the-new-pokemon-with-guns-survival-game-everyones-playing). Interestingly, Pocket Pair's own webpage for Craftopia includes the Pokemon trademarked slogan of "Gotta Catch 'Em All!" – https://www.pocketpair.jp/craftopia.

    [9] https://www.ign.com/articles/the-pokemon-company-makes-an-official-statement-on-palworld-we-intend-to-investigate  

    [10] https://youtu.be/b5W1OFnnj4w?si=DwxJRNFo_N8l7Q4h&t=237  

    [11] If you would like to see an EU / UK lawyer's brief thoughts on the matter, see https://www.rockpapershotgun.com/does-palworld-break-pokemons-copyright-we-asked-a-lawyer   

    [12] https://www.law.cornell.edu/uscode/text/17/102

    [13] Atari, Inc. v. Amusement World, Inc., 547 F. Supp. 222 (D. Md. 1981); Tetris Holding, LLC v. Xio Interactive, Inc., 863 F. Supp. 2d 394 (D.N.J. 2012); see also Applying Copyright Law to Videogames: Litigation Strategies for Lawyers, John Quagliariello, Harvard Journal of Sports & Entertainment Law, Vol. 10

    [14] https://mluce.ro/articles/the-yokai-roots-of-pokemon/

    [15] https://bulbapedia.bulbagarden.net/wiki/Vulpix_(Pok%C3%A9mon); https://bulbapedia.bulbagarden.net/wiki/Ninetales_(Pok%C3%A9mon); https://palworld.fandom.com/wiki/Foxparks; https://palworld.fandom.com/wiki/Foxcicle; https://palworld.fandom.com/wiki/Kitsun

    [16] https://en.wikipedia.org/wiki/Digimon_World; https://en.wikipedia.org/wiki/Temtem        

    [17] https://www.videogameschronicle.com/news/palworld-pokemon-plagiarism-accusations-pile-up-as-ceo-responds/   

    [18] https://www.pcgamer.com/palworld-accused-of-copying-pokemon-models-developer-pushes-back-says-artists-are-being-slandered/    

    [19] See, e.g., Meshwerks v. Toyota Motor Sales U.S.A., Inc., 528 F.3d 1258 (10th Circuit, 2008)   

    [20] https://bulbapedia.bulbagarden.net/wiki/Miltank_(Pok%C3%A9mon)      

    [21] https://www.polygon.com/24047136/palworld-pokemon-mod-release-toastedshoes   

    [22] https://www.destructoid.com/nexus-mods-bans-pokemon-based-content-for-palworld/     

    [23] 17 U.S.C. § 106(2)      

    [24] https://www.copyright.gov/circs/circ14.pdf      

    [25] https://www.rockpapershotgun.com/palworlds-skin-deep-pokemon-parody-is-part-of-a-bigger-horror-story       

    [26] For an interesting rebuttal to the rockpapershotgun parody article reference above, see https://www.themarysue.com/palworld-why-a-pokemon-parody-may-be-considered-fair-use-but-satire-isnt/

    [27] See, e.g., Leovy v. Google (N.D. Cal.); Nazemian v. NVIDIA Corporation (N.D. Cal.); Tremblay v. OpenAI (N.D. Cal.); Silverman v. OpenAI (N.D. Cal.); Chabon v. OpenAI (N.D. Cal.); New York Times v. Microsoft and OpenAI (S.D.N.Y.)

    [28] https://www.thefashionlaw.com/from-chatgpt-to-deepfake-creating-apps-a-running-list-of-key-ai-lawsuits/

    [29] Williams v. Gaye, 895 F.3d 1106 (9th Cir. 2018)

    [30] This situation can be analogized to Authors Guild, Inc. v. Google, Inc. (2nd Cir. 2015), in which Google digitized copyrighted works and displayed snippets of them in response to a search, and the court found that such a use was transformative enough to constitute a fair use.

    [31] 18 U.S.C. § 1836; 18 U.S.C. § 1839(5)

    [32] https://gamerant.com/pokemon-professor-oak-quotes-ranked/

  • By Kevin E. Noonan –

    Judge Newman_1Over the past year suspended Federal CIrcuit Judge Pauline Newman's lawsuit (see "Judge Newman and the On-Going Attempts to Remove Her from the Federal Circuit") against Chief Judge Kimberly Moore, and Circuit Judges Sharon Prost and Richard Taranto (in their roles as members of the Special Committee of the Judicial Council of the Federal Circuit responsible for the Order suspending Judge Newman) has continued without much fanfare.  However, in the face of Defendant's Motion for Judgment on the pleadings the status quo is likely to change no matter now the District Court rules.

    The opening paragraph of Judge Newman's brief opposing Defendant's motion demonstrates her intention not to go quietly.  The brief avers that Chief Judge Moore "unilaterally" removed Judge Newman from the bench, the suspension being "extended by an unprecedented, unrecorded and unpublished vote of the Defendant Judicial Council" in a meeting that was "neither noticed nor memorialized."  Only after this suspension, the brief asserts, did the Chief Judge "instigate[]" an investigation over alleged physical infirmities (a heart attack and a fainting episode) that "Defendants themselves now acknowledge were false."  These actions constitute a "pattern of harassment" that "continues unabated to the present day" according to the brief, an allegation illustrated by refusing to permit Judge Newman to hire a judicial assistant (to which in her status as a Circuit Court judge she was entitled to do), removing the Judge from an internal e-mail distribution list, which deprived Judge Newman of information about the Court's business, and refusing her request to extend the term of one of her clerks.  The Chief Judge and the Judicial Council were able to take these steps, according to the brief, because the legal authority they are based upon, the Judicial Conduct and Disability Act ("Disability Act"), 28 U.S.C. §§ 351–364, "unconstitutionally vest unfettered discretion in Defendants, which permits them, without impeachment, for all intents and purposes, to divest an Article III judge of her office."

    To recap, the legal grounds for Judge Newman's complaint were the following:

    Claim I asserts "improper removal [and] violation of separation of powers" based on Article III (life tenure of federal judges) and Article I (giving the House of Representatives the sole authority to remove a judge through impeachment after trial by the Senate). 

    Claim II asserts that the Judicial Complaint is ultra vires for "improper removal [and] violation of separation of powers."  This allegation is based on Judge Newman being removed from her duties before the special committee's investigation was concluded (which removal the Judicial Disability Act of 1980 codified at 28 U.S.C. § 354(a)(2)(A)(i) requires to be after the investigation according to the complaint).

    Claim III alleges Fifth Amendment violations of due process because the members of the Special Committee are also purported witnesses to the alleged judicial misconduct (the complaint stating that "[i]t has been established for centuries that one cannot serve as a 'judge in his own cause'").

    Claim IV asserts a First Amendment violation for unlawful prior restraint for the gag order, contrary to several Supreme Court cases prohibiting prior restraint on speech (Houston Cmty. Coll. Sys. v. Wilson, 142 S. Ct. 1253, 1259 (2022) (the First Amendment prohibits prior restraint on speech) and Alexander v. United States, 509 U.S. 544, 550 (1993)).

    Claim V asserts that the gag order is also ultra vires as being an unlawful prior restraint on speech.

    Claim VI asserts a Fifth Amendment violation for unconstitutional vagueness of the provisions of the Disability Act.

    Claim VII asserts that the activities are ultra vires for unconstitutional examination because "[n]either the Act nor the U.S. Constitution authorizes compelling an Article III judge to undergo a medical or psychiatric examination or to surrender to any investigative authority her private medical records in furtherance of an investigation into whether the judge suffers from a mental or physical disability that renders her unable to discharge all the duties of office."

    Claim VIII asserts a Fifth Amendment violation for unconstitutional vagueness regarding the Act's investigative authority, with regard to "authoriz[ing] compelled medical or psychiatric examinations of Article III judges or demands from special committees for Article III judges to surrender their private medical records."  In particular, this allegation is directed to Section 353(c) of the Act.

    Claim IX alleges a Fourth Amendment violation for an unconstitutional search regarding the "compelled medical or psychiatric examination of an Article III judge without a warrant based on probable cause and issued by a neutral judicial official or a demonstration of constitutional reasonableness."

    Claim X alleges a Fourth Amendment violation for an unconstitutional search and seizure of a "compelled surrender of private medical records."

    Claim XI alleges a Fourth Amendment violation for "lack[ing] either a warrant issued on probable cause by a neutral judicial official or a constitutionally reasonable basis for requiring Plaintiff to submit to an involuntary medical or psychiatric examination."

    Claim XII alleges a Fourth Amendment violation for "lack[ing] either a warrant issued on probable cause by a neutral judicial official or a constitutionally reasonable basis for requiring Plaintiff to surrender her private medical records none of which bear on her fitness to continue serving as an Article III judge."

    Judge Newman's legal arguments are that, first, as an Article III judge she is "constitutional officer of this Republic, and not merely a federal employee" who "does not have a supervisor and does not need to meet any performance metrics to keep her job."  "Congress alone has the power to remove her," the brief asserts.

    Second, the operative statute, the Disability Act, lacks a definition of what constitutes a disability nor what factors are to be considered.  Rather than relying on medical professionals, the brief asserts, the determination is left "in the hands of lay people like Chief Judge Moore and her colleagues, all without providing them with any tools to determine when a disability exists."

    Third, there is no provision in the statute for judicial review of any Orders or actions taken pursuant to the statute, permitting violations of the Fourth Amendment including "invasive searches of private medical information" and allowing "self-executing" administrative orders to be promulgated by the Judicial Council, "a wholly administrative body."  The result is a regime where the Council can "employ and manipulate entirely standardless criteria in order to start and to continue investigations into and to impose unconstitutional sanctions on Article III judges."  In this regard, the brief reminds the District Court that the putative grounds and factual justifications for the Council's Orders have "evolved" in the year since the proceedings began.

    The District Court previously dismissed Counts II, III, IV, VI, X and XI for lack of subject matter jurisdiction and Count I and parts of Count VII under Fed. R. Civ. P. 12(b)(6).  Thus, only Courts V, VII, VIII, and IX remain and are the subject of the Defendant's Motion for Judgment on the Pleadings and Judge Newman's motion in opposition thereto.  The arguments Judge Newman through counsel asserts for these remaining Counts are that the Disability Act is unconstitutionally vague in defining what is a disability under the Act (Count V) and "its grant of investigative authority to the Special Committee (Count VII)" and that the Act authorizing the Council to "demand medical examinations and private medical records as a condition for maintaining one's Article III judicial office[] violates the Fourth Amendment's prohibition on unreasonable searches."

    The brief sets forth the standard of review for a facial challenge to a statute authorizing warrantless searches to be a showing that the searches authorized by the statute are "unreasonable," citing City of Los Angeles, Cal. v. Patel, 576 U.S. 409, 419-20 (2015).  Such a challenge can be brought when a law threatens to inhibit the exercise of constitutionally protected rights or allows for arbitrary and discriminatory enforcement the brief argues, citing Vill. of Hoffman Ests. v. Flipside, Hoffman Ests., Inc., 455 U.S. 489, 499 (1982).  Importantly, the brief further argues that Judge Newman does not need to show that the Disability Act is unconstitutional in all of its applications, but rather that it creates "a danger of arbitrary and discriminatory enforcement" or "threatens to inhibit the exercise of constitutionally protected rights," citing Hoffman Ests, 455 U.S. at 494, 498.

    Regarding Counts VIII and IX, Judge Newman's argument relates to the constitutionality (or lack of it) of the scope and type of searches the Disabilities Act permits (at least as demanded by this Judicial Council), specifically the "investigation" provision, 28 U.S.C. § 353(c).  The brief argues that this scope in practice violates Fourth Amendment prohibitions against unlawful searches and seizures, specifically "by authorizing special committees to compel medical examinations and the production of medical records without a warrant or a demonstration of constitutional reasonableness."  The challenges are "facial, not as applied," citing City of Los Angeles v. Patel for the standard that a facial challenge is not required to show that a law is unconstitutional in all of its applications, countering the Defendant's position that the existence of some legitimate searches rebuts Judge Newman's facial challenge.  The brief cites additional language from the Supreme Court that "when assessing whether a statute meets this standard, the Court has considered only applications of the statute in which it actually authorizes . . . conduct" (emphasis in brief); 576 U.S. at 418.  Accordingly, instances where a search under the Disabilities Act is performed with acquiescence or consent are irrelevant to the legal inquiry under Patel.  Indeed, according to the brief a requirement in a facial challenge of a showing of unconstitutionality in all of a statute's applications "would preclude facial relief in every Fourth Amendment challenge to a statute authorizing warrantless searches" under Patel.

    The brief also argues that the Disability Act violates the Fourth Amendment because while the Judicial Committee's orders may be based on "reasonable suspicion" of the subject judge's disability, under the Fourth Amendment searches conducted outside the judicial process without a warrant must have a showing of constitutional reasonableness that is absent here.  Moreover, the brief asserts that the "special needs" exception, which applies to certain administrative searches, does not apply to the Disability Act because obtaining a warrant is not impracticable in this case and the burden of obtaining a warrant would not frustrate the government's purpose behind the search.  ​The "special needs" exception applies, according to the brief, when "special [government] needs, beyond the normal need for law enforcement, make the warrant and probable-cause requirement impracticable," citing Vernonia Sch. Dist. 47J v. Acton, 515 U.S. 646, 653 (1995) (quoting Griffin v. Wisconsin, 483 U.S. 868, 873 (1987)) (emphasis in brief).  That is not the case here, where the acceptable standard for impracticability is not satisfied (being that obtaining a warrant must "seriously disrupt the routine conduct of business," citing O'Connor v. Ortega, 480 U.S. 709, 722 (1987), or "when 'the burden of obtaining a warrant is likely to frustrate the governmental purpose behind the search,'" citing New Jersey v. T.L.O., 469 U.S. 325, 340 (1985) (quoting Camara v. Municipal Court, 387 U.S. 523, 533 (1967)).  And even should Defendants be able to make such a showing, whether a warrant is required is subject to a "balancing test" between government interests and individual privacy interests, under Skinner v. Railway Lab. Execs.' Ass'n, 489 U.S. 602, 619 (1989)).  Judge Newman argues that the cumulative impact of this case law is that Defendants were required to show both that the special exception applies and that obtaining a warrant would have been impracticable, which they did not do, according to her brief, providing an analysis and assessment of the cases advanced by Defendants in support of their position and the inapplicability thereof ("it should be noted that Judge Newman is not an employee, but an independent constitutional officer and that neither Chief Judge Moore, nor the Special Committee, nor the Judicial Council are her 'supervisors'" as was the case in many of the decisions cited by Defendants in their Motion).

    The brief takes particular apparent umbrage at assertions in Defendant's Motion to Dismiss that "special committees can require medical examinations without a warrant because 'psychological testing and psychiatric interviews are a routine feature of occupations which involve stress and sensitive interpersonal contact,'" and that in this respect, "[t]here is no reason to distinguish between [government] employees and judicial officers."  First, the brief asserts that "there is an obvious need to distinguish mere employees who constitutionally speaking are not meant to be independent or to enjoy any tenure protections and Article III judges who enjoy such protections precisely because they are meant to be independent."  Second, the brief challenges the assertion that subjecting Article III judges to such medical examinations is routine, stating that "an Article III judge has never before undergone compelled medical testing of any kind . . . [i]n the 44 years the Disability Act has been in effect (and the 235-year history of the federal judiciary), medical testing has been ordered once and has never taken place" (and in that case the Judicial Council discontinued their efforts when the judge contested the Order).  Unlike the governmental employees in the cases Defendants asserted in support of their Motion to Dismiss, Judge Newman asserts that "Article III judges are officers of the United States, appointed by the President with the advice and consent of the Senate, [that] "hold their positions for life" and "the Constitution and the Supreme Court guard these judges' independence," citing Mistretta v. United States, 488 U.S. 361, 410 (1989), for the latter proposition and for the proposition that "no Act can authorize the President (or by extension anyone else) "to remove, or in any way diminish the status of Article III judges, as judges" (emphasis in brief).  Article III judges "are removable only by the Senate, not by a supervisor who might search their offices or subject them to medical testing, and not by their circuit's judicial council" under Mistrella the brief argues.  Finally, adopting Defendants' position would deny Article III judges from judicial review "both ex ante and ex post" putting the judge in a less favorable position ("have less constitutional protection") than other governmental employees (emphasis in brief).  And being thus denied judicial review is exacerbated by Judicial Councils, as Defendants would have it, being "investigator, judge, and jury—and even, if necessary, witnesses."

    Even if the special needs exception could apply, according to Judge Newman, the District Court cannot determine at the pleadings stage whether a warrantless search is reasonable.  The requirement for a balancing test under the Fourth Amendment between governmental rights and individual privacy rights is inconsistent with dismissing Judge Newman's challenge to the Judicial Council's actions without the District Court having the opportunity to consider the evidence (and Judge Newman ​the opportunity to present such evidence) (and even if the Court were to do so on the current record Judge Newman argues Defendants' motion should be denied) according to the brief.

    Judge Newman further argues that the Disability Act fails to articulate any standard for "judicial disability," contrary to other Acts of Congress related to disabilities in other contexts.  The history of the Act is evidence of this standardlessnes, "[b]egin[ning] with this case," Judge Newman asserts:

    Throughout both this litigation and the administrative process within the Judicial Council, Defendants have not even been able to articulate what judicial duties Judge Newman is unable to perform.  At most, they have alleged that Judge Newman is able to perform those duties slowly.  Defendants have not been able to point to a single opinion (whether majority, concurring, or dissenting) that was not well-written or otherwise fell below any conceivable standard of judicial craftsmanship.  Nor have they pointed to any behavior that Judge Newman may have exhibited on the bench or in conference that indicates (or would even cause one to suspect) an inability to perform the functions of judicial office.

    Indeed, the "disability" allegations against Judge Newman throughout these proceedings read like a Chinese menu with Defendants making and withdrawing seemingly haphazard allegations.  For example, in the initial order launching administrative proceedings against Judge Newman, Chief Judge Moore alleged (based apparently on a thirdhand remark from Judge Newman's former judicial assistant) that she suffered a heart attack.  But no explanation was given as to why a heart attack—a not uncommon malady—would make one unable to perform duties of an appellate judge.  The same goes to the allegations (also erroneous and apparently since abandoned) that Judge Newman had a fainting spell and had difficulty walking significant distances.  Surely, an ability to walk without resting is not even remotely indicative of one's ability to reason through and write about legal issues.  Yet, it was these allegations that allowed Chief Judge Moore to kick-start the administrative process against Judge Newman.

    (The brief includes several other statements by other members of the Judicial Council supporting Judge Newman's argument of the standardlessness of the term "judicial disability," as well as examples of other conditions having more significant impacts on a judge's ability to perform her duties, that have not provided a basis for suspending her from the bench.)  The situation is worsened, as the brief sets out, because "[a]t no point have the Defendants ever suggested that were Judge Newman to receive medical clearance the administrative proceedings against her would be terminated and she would be restored to the calendar," which "further confirms the latent subjectivity at play."

    Finally, Judge Newman asserts that the Act's grant of unfettered investigatory authority fails to articulate any standards for launching or continuing an investigation or for demanding cooperation, and is therefore void for vagueness.  (Such investigations "have no boundaries," which circumstances permit "arbitrary and discriminatory enforcement.")  The role of gatekeeper imposed on the Chief Judge under the Act in determining whether a complaint is sufficient to commence proceedings such as this one is "simply ouroboric" insofar as the statute provides no definition for the Chief Judge to apply in making her determination.  The brief further asserts that Judge Newman does not object to being investigated ("[i]n this country, anyone is free to 'investigate' anyone for any reason and on any topic.  To the extent that Defendants wish to ask questions, write reports, and even urge Congress to remove Judge Newman, they are free to do so").  The issue, and the significance of the statutory vagueness, is "whether Defendants can compel Judge Newman to turn over private documents and then directly sanction her for declining to do so") (emphasis in brief).  As a consequence:

    [A] Chief Judge (and then the Special Committee) can decide, without meeting any standards whatsoever, to launch the investigation, expand it, request whatever records they deem appropriate, and then impose self-executing sanctions (without any outside supervision by an Article III court) all without the benefit of a clearly defined standard of behavior for the judge being investigated to adhere to.  And as this very case shows, because the Act confers such an unlimited power on Defendants, it authorizes them to conduct an interminable investigation and to continue sanctioning a judge in Plaintiff's position whenever the Plaintiff does not completely accede to whatever demands a Special Committee or a Judicial Council might conjure up[.]

    (which is true even should a Chief Judge "make entirely unsubstantiated allegations" and then "empanel a special committee which can then proceed to an investigation entirely untethered from the initial allegations," a position consistent with the Council's own arguments and assertions earlier in the course of this case according to Judge Newman).

    "In short, the Act's combining of the power to investigate without any limits or well-defined causes with the power to sanction a subject judge who declines the outlandish demands that accompany the investigation renders the provision unconstitutionally vague," Judge Newman's brief concludes.

    The District Court is expected to rule on Defendants' Motion to Dismiss the remaining Counts of Judge Newman's complaint in due course after the Judicial Council files its Reply brief.

  • By Kevin E. Noonan –

    Federal Circuit SealThe Federal Circuit handed down an opinion earlier this month that invalidated several asserted claims and found infringement under 35 U.S.C. § 271(e)(2) of the claims, while refusing to modify its judgment on infringement after Defendant Norwich submitted a revised ANDA containing a Section viii "carveout" in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc.  The majority opinion raises issues in its invalidity analysis regarding the extent to which the prior art should be required to disclose the recited administered dose to satisfy the "reasonable expectation of success" prong for obviousness for pharmaceutical claims (wherein the standard adopted by the majority motivated Judge Cunningham to dissent in part).  The reasoning provided by Judges Lourie and Chen appeared to be rooted in the broader scope of creativity imparted to the skilled artisan under KSR v. Teleflex as discussed below.

    The case arose in ANDA litigation over rifaximin, the active ingredient in Salix's commercial product Xifaxan®, which the opinion informs has been used as an antibiotic for 40 years.  The use at issue was FDA-approved treatment of irritable bowel syndrome with diarrhea (IBS-D) and hepatic encephalopathy (HE), specified in each instance by treatment with 550 mg doses three times per day (TID) for a total of 1650 mg administered dose.  Salix asserted three "groups" of patents:

    • U.S. Patent Nos. 8,624,573, 9,421,195, and 10,335,397 directed to HE treatment;
    • U.S. Patent Nos. 8,309,569 and 10,765,667 directed to treating IBS-D using the 550 mg TID administration protocol; and
    • U.S. Patent Nos. 7,612,199 and 7,902,206 directed to rifaximin polymorph b

    The District Court held* that claim 2 of U.S. Patent No. 8,309,569, claim 3 of U.S. Patent No. 10,765,667, claim 4 of U.S. Patent No. 7,612,199, and claim 36 of U.S. Patent No. 7,902,206 were obvious, and that claim 8 of U.S. Patent No. 8,642,573, claim 6 of U.S. Patent No. 9,421,195, and claims 11 and 12 of U.S. Patent No. 10,335,397 were not invalid and infringed, and entered judgment that the FDA not approve Norwich's ANDA for HE indications until the final patent in this group expired in October 2029.  Norwich amended its ANDA to provide a Section viii "carveout" of indications related to HE treatment and filed a motion to modify the judgment under Fed. R. Civ. Pro. 60(b) which the District Court denied.  This appeal by both parties of the adverse decisions below followed.

    The Federal Circuit affirmed, in an opinion by Judge Lourie joined by Judge Chen in toto and by Judge Cunningham in part, who also dissented in part.  Regarding obviousness of claims to IBS-D treatment, the opinion sets forth claim 2 of the '569 patent as being representative:

    1.  A method of providing acute treatment for diarrhea-associated Irritable Bowel Syndrome (dIBS) comprising: administering 1650 mg/day of rifaximin for 14 days to a subject in need thereof, wherein removing the subject from treatment after the 14 days results in a durability of response, wherein the durability of response comprises about 12 weeks of adequate relief of symptoms.

    2.  The method of claim 1, wherein the 1650 mg is administered at 550 mg three times per day.

    The District Court's decision was based on the combination of a Phase II clinical trial protocol disclosing twice-daily dosing of IBS patients with 550 mg doses (1100 mg total) or 1100 mg doses (2200 mg total) of rifaximin (the opinion noting that "the Protocol does not include any efficacy or safety data, nor does it mention a 1,650 mg/day dose or TID dosing"), taken in view of a scientific journal article to Pimentel that disclosed treating IBS with administration of 400 mg of rifaximin TID (for a total of 1,200 mg); significantly for the Federal Circuit's decision, this reference contained a speculative statement that "optimal dosage of rifaximin may, in fact, be higher than that used in our study."  These references were used by the District Court to provide a motivation to combine them with a reasonable expectation of success, and the majority agreed (Judge Cunningham adducing here disagreement on this point in her dissent).  Salix argued that the District Court erred in the reasonable expectation of success prong of this analysis, which as a question of fact required a showing of clear error on appeal.  Curiously, Salix (according to the opinion) did not dispute the District Court's finding that all limitations of claims to IBS-D treatments were "effectively disclosed" in the cited art, despite there being no express disclosure of administering 550 mg rifaximin TID (for a total of 1650 mg) (other than the speculation in the scientific reference that higher doses may be optimal).

    The Federal Circuit majority restricted the application of its conclusion that this prior art disclosure supports a finding that there is a reasonable expectation of success under these circumstances by asserting that:

    Although we have rejected the idea that "efficacy data [are] always required for a reasonable expectation of success," OSI Pharms., LLC v. Apotex Inc., 939 F.3d 1375, 1385 (Fed. Cir. 2019), we are hesitant to conclude as a general matter that the disclosure of a Phase II clinical trial plan, standing alone, provides an expectation of success sufficient to render obvious a dosage that was not included within the planned clinical trial.

    However, the majority distinguished the situation here by the combination of the clinical trial protocol with the Pimentel reference.  For the majority, that speculative sentence, that "[r]ecent data suggest that the optimal dosage of rifaximin may, in fact, be higher than that used in our study" was sufficient to create in the skilled artisan sufficiently reasonable expectation of success to satisfy the requirement for finding obviousness (emphasis in opinion), at least in view of the clear error standard of review.  The majority's reasoning was that Pimentel expressly disclosed 400 mg rifaximin TID and that "the next higher dosage unit from the Protocol was 550 mg" combined with the unsupported suggestion that higher doses may be optimal.  This conclusion was supported in the majority's view by the Court's earlier precedent that "certainty and absolute predictability are not required to establish a reasonable expectation of success, citing Almirall, LLC v. Amneal Pharms. LLC and Acorda Therapeutics, Inc. v. Roxane Lab'ys, Inc.  The majority also cited several "references establishing the background knowledge of a person of ordinary skill in the art" consistent with their finding of no clear error in the District Court's obviousness determination (although, as explicated in the dissent these references were not considered by the District Court).  The majority appeared to have been satisfied that ex post facto verification of the skilled artisan's purported expectation of success using increased dosage amounts supports its reasonableness beforehand.  The majority similarly used this reasoning to credit the skilled artisan of apprehending that administering increased dosages would not create "an intolerable increase in negative side effects."  And the majority also asserted that there had been "[w]idespread off-label use" of rifaximin for treating IBS-D that supported this safety expectation.

    Similarly the Court (Judge Cunningham not dissenting from this aspect of the judgment) affirmed the District Court's determination that claims to the β-polymorph of rifaximin would have been obvious.  Claim 4 of the '199 patent was set forth in the opinion as representative:

    4.  Rifaximin in polymorphic form β, wherein the rifaximin has x-ray powder diffraction pattern peaks at about 5.4°; 9.0°; and 20.9°2θ and wherein the rifaximin has a water content of greater than 5%.

    The prior art disclosed preparations of crystalline rifaximin (albeit not the β-polymorph expressly) and methods for preparing such crystalline forms including in particular solvents used to prepare them (it being recognized that in the arcane rituals of crystallization such solvent choice frequently determines the resulting crystalline product).  The panel noted that the District Court's factual determinations supporting its obviousness conclusions were supported by expert testimony that "(1) a skilled artisan would have had good reason to characterize the crystalline rifaximin obtained by following the Cannata protocols, (2) that such characterization was routine and could have been performed 'in one day,' and (3) that doing so would have led the skilled artisan to have 'detected rifaximin β.'"  The Federal Circuit also distinguished prior precedent including Grunenthal GmBH v. Alkem Laboratories Ltd., 919 F.3d 1333 (Fed. Cir. 2019), and Pharmacyclics LLC v. Alvogen, Inc.; regarding Grunenthal, the panel asserted that the prior art produced one particular polymorph and that the art disclosed no evidentiary basis to expect that a second form would be produced using prior art guidance regarding "what particular solvents, temperatures, agitation rates, etc., were likely to result" in the claimed polymorphic form, which conclusion the Federal Circuit held was not clear error.  The panel here maintained that this precedent merely showed the reliance on particular factual aspects involved in such decisions, citing Sanofi-Synthelabo v. Apotex, Inc. and Pfizer, Inc. v. Apotex, Inc.  A particular distinction persuasive to the Court was that in Grunenthal there was a question of whether the skilled artisan could produce a crystalline form of the claimed compound, which was not the case here (the parties agreeing that methods for preparing crystalline rifaximin were established in the prior art, as well as there being an appreciation in the art that "polymorph β is a commonly produced polymorph and the most stable form of rifaximin").  While abjuring a conclusion that there would always be a reasonable expectation of success in producing the β-rifaximin polymorph the panel found no clear error in the District Court's fact finding here and thus affirmed.

    (Regarding Pharmacyclics its status as a non-precedential decision put squarely within the District Court's discretion its decision not to follow its conclusions, as well as stating that the Court's "later affirmance of the factual findings in Pharmacyclics did not retroactively override the district court's analysis here.")

    The panel assessed Norwich's appeal of the District Court's decision that, as a consequence of its ANDA constructively infringing Salix's claims to methods for treating HE it was correct in ordering that a final approval of Norwich's ANDA could not be effective before the HE patents expired under 35 U.S.C. § 271(e)(4)(A) as a question of statutory interpretation.  In this regard, the opinion notes that the statute instructs that "the court shall order the effective date of any approval of the drug or veterinary biological product involved in the infringement to be a date which is not earlier than the date of the expiration of the patent which has been infringed."  Norwich contended that this mandate includes the requirement that the order take into consideration (and is limited to) the indication for which an ANDA applicant seeks approval.  The basis for this argument was that Norwich's original ANDA had indications for both HE and IBS-D and the District Court's infringement determination was limited to the HE indication.  While Norwich voiced its concern that this Order would "unfairly preclude[] it from receiving final approval of a new non-infringing ANDA" the opinion flatly rejects this concern ("The district court did no such thing")(arguably thus receiving the Federal Circuit's imprimatur for any such filing of such an ANDA successfully).  The statutory construction bases for this conclusion by the panel is that FDA approves drugs for specific and particular indications and thus proper construction is "directed to approval of particular infringing uses of the drug, not all uses of the drug including non-infringing uses."  This limits the scope of infringement to submission of an ANDA to the infringing use under 35 U.S.C. § 271(e)(2)(A).  But "[t]he order appropriately said nothing that would prevent approval of a new non-infringing ANDA."

    Regarding the panel's affirmance of the District Court's denial of Norwich's Rule 60(b) motion, the Federal Circuit asserted that the question was whether that denial was an abuse of discretion under Third Circuit law, citing Amstar Corp. v. Envirotech Corp., 823 F.2d 1538, 1550 (Fed. Cir. 1987).  The opinion states that a district court can reconsider its infringement finding when a defendant files an amended ANDA but is not compelled to do so, citing Ferring B.V. v. Watson Lab'ys, Inc. Fla.  Here, the Federal Circuit appreciated that "[i]t is not a simple matter to determine whether an ANDA applicant has successfully carved out language from a label to turn infringement into non-infringement" and Norwich's motion would amount to "essentially" a second litigation.  Because under Third Circuit law there is no obligation to grant such a motion the panel discerned no abuse of that discretion in this case.

    Judge Cunningham's dissent was limited to the Court's affirmance that the asserted claims in the '569 and '667 patents were invalid for obviousness.  In Judge Cunningham's opinion, Norwich has satisfied its burden to convince the Judge that she is "'left with the definite and firm conviction that a mistake has been committed' regarding these findings," citing Pfizer, Inc. v. Apotex, Inc. (quoting United States v. U.S. Gypsum Co., 333 U.S. 364, 395 (1948)).  The basis of this conviction is the disconnect the Judge apprehends regarding the disclosure of the cited art (400 mg TID, 1200 mg/day in Pimentel or 550 mg BID or 1100 mg/day) and the scope of the claims (550 mg TID, 1650 mg/day).  There was just as great a likelihood in the Judge's mind that the 1100 mg/day dose would have implied that higher doses would not lead to more successful results, inter alia because the tested 2200 mg/day dose did not.  And the citations of the later-arising references don't cure these analytical deficiencies on the merits because they teach 1200 mg/day wherein the claimed invention recited dosages "almost 40% higher."  Anecdotal reference to off-label use was also unavailing in the Judge's opinion to support the purported reasonable expectation of success because there was no disclosure of dosages therein.  Requiring a correspondence between the recited dosages and the cited prior art is consistent with other Federal Circuit precedent including In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Pat. Litig. and Ferring B.V. v. Watson Lab'ys, Inc.-Fla.  The single sentence in the Pimentel reference also drew the Judge's attention, wherein "the lack of discussion of any actual dosage that may be optimal, the use of the word 'may,' and the fact that the RFIB 2001 Protocol discloses a specific dosing regimen of 2,200 mg/day rather than 1,650 mg/day all call into question the majority's finding" in Judge Cunningham's opinion.  It had also not escaped the Judge's attention that this sentence was considered by the District Court for the motivation to combine requirement and not the reasonable expectation of success prong of the obviousness analysis.  Finally, Judge Cunningham would decline to assess the significance and content of the after-arising art in the first instance, because none of this art provided any basis for the District Court's decision and thus had made no findings of fact regarding it, citing Golden Bridge Tech., Inc. v. Nokia, Inc., 527 F.3d 1318, 1323 (Fed. Cir. 2008).  The first order of business for the district court on remand (if Judge Cunningham's views had prevailed) would be to consider the significance of this art, see, ACS Hosp. Sys., Inc. v. Montefiore Hosp., 732 F.2d 1572, 1578 (Fed. Cir. 1984).

    * The totality of these claims at issue were:

    U.S. Patent No. 8,309,569

    2.  A method of providing acute treatment for diarrhea-associated Irritable Bowel Syndrome (dIBS) comprising: administering 1650 mg/day of rifaximin for 14 days to a subject in need thereof, wherein removing the subject from treatment after the 14 days results in a durability of response, wherein the durability of response comprises about 12 weeks of adequate relief of symptoms, wherein the 1650 mg is administered as 550 mg three times per day.

    U.S. Patent No. 10,765,667

    3.  A method of treating one or more symptoms of irritable bowel syndrome (IBS) in a subject 65 years of age or older, said method comprising administering, 550 mg of rifaximin TID for 14 days to the subject, thereby treating one or more symptoms of IBS in the subject 65 years of age or older, wherein the IBS is diarrhea-predominant IBS.

    U.S. Patent No. 7,612,199

    4.  Rifaximin in polymorphic form β, wherein the rifaximin has x-ray powder diffraction pattern peaks at about 5.4°; 9.0°; and 20.9°2θ and wherein the rifaximin has a water content of greater than 5%.

    U.S. Patent No. 7,902,206

    36.  A solid pharmaceutical composition comprising rifaximin in polymorphic Form β and a pharmaceutically acceptable excipient or carrier, wherein the rifaximin Form β has x-ray powder diffraction pattern peaks at about 5.4°; 9.0°; and 20.9° 2-θ, wherein the rifaximin Form β has a water content of between about 4.5% to about 40%.

    U.S. Patent No. 8,642,573

    8.  A method of maintaining remission of hepatic encephalopathy (HE) in a subject in need thereof comprising administering between about 1000 mg to about 1200 mg rifaximin daily to the subject for a period of 12 months or longer, thereby maintaining remission of HE, wherein remission is defined as a Conn score of 0 or 1.

    U.S. Patent No. 9,421,195

    6.  A method of reducing the risk of hepatic encephalopathy (HE) recurrence in an adult subject in need thereof comprising:
        
    orally administering between about 1000 mg to about 1200 mg of rifaximin daily to the adult subject for a period of 12 months or longer, thereby reducing the risk of hepatic encephalopathy (HE) recurrence,
        
    comprising orally administering about 1100 mg of rifaximin per day to the adult subject,
    and
        orally administering about 550 mg of rifaximin twice daily to the adult subject.

    U.S. Patent No. 10,335,397

    11.  A method of reducing a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (HE) episode, comprising administering to the subject between about 1000 mg to about 1200 mg of rifaximin daily for a period of about 12 months or longer, wherein the subject has a Conn score of 0 or 1, wherein the rifaximin is administered orally, wherein 1100 mg of rifaximin is administered per day, and wherein 550 mg of rifaximin is administered twice daily.

    12.  A method of reducing a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (HE) episode, comprising administering to the subject between about 1000 mg to about 1200 mg of rifaximin daily for a period of about 12 months or longer, wherein the subject has a Conn score of 0 or 1, further comprising administering lactulose.

    In each instanced italics denotes independent claims from which the asserted claims depend.

    Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc. (Fed. Cir. 2024)
    Panel:  Circuit Judges Lourie, Chen, and Cunningham
    Opinion by Circuit Judge Lourie; opinion dissenting-in-part by Circuit Judge Cunningham